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Abstract: Ovarian cancer is the most life-threatening of all gynecologic malignancies 
with survival rate of about 30% that often has few symptoms prior to late stage diagnosis. 
Ovarian cancer causes 5 percent of cancer deaths among US women. In 2018 
approximately 22,240 new cases of ovarian cancer were diagnosed in the United States 
and 14,070 died. Cisplatin and taxane drugs usually have unacceptable side effects. 
SHetA2 is an anticancer compound that has exhibited strong activity against ovarian 
cancer. It has discriminatory activity against malignant cells versus normal cells and has 
very low toxicity. SHetA2 is a sulfur containing Flex-Het with the highest anti-cancer 
activity among the tested Flex-Hets. SHetA2 has been shown effective against all of over 
60 cancer cell lines in the US National Cancer Institute. SHetA2 interacts with heat shock 
protein HSPA9/mortalin. Mortalin was shown to associate with the tumor protein p53 in 
a concentration-dependent manner and leads to inactivation of p53 apoptotic function in 
stressed cells. Since p53 has a major role in cell cycle arrest and apoptosis, the loss of 
p53 function leads to immortalization of cells. Protein p53 is nonfunctional in some 
tumors by cytoplasmic sequestration of its binding proteins, such as Bcl-2, 
hsp70/mortalin, Parc, PML, and cytoskeleton proteins. One pathway for the compounds 
to inhibit the growth of cancer cells in vitro is by displacing p53 from mortalin. Then, 
p53 migrates to the nucleus and initiates apoptosis. Binding of SHetA2 to mortalin 
interrupts p53-mortalin interaction, and releases protein p53 to nucleus where it initiates 
apoptosis. Study of the interactions between mortalin and SHetA2 as well as the 
interactions between mortalin and SHetA2 analogs is the subject of this study. We used 
solution state NMR spectroscopy technique (chemical perturbation method) and 
molecular mechanics approaches (Autodock tools and molecular dynamics via 
GROMACS) to study protein-ligand interactions. We investigate the binding site and 
binding affinity using these techniques. Our findings helped designing improved SHetA2 
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Nuclear Magnetic Resonance (NMR) spectroscopy addresses the behavior of nuclear spin 
angular momentum, which is an intrinsic quantum mechanical property, in the presence of 
magnetic fields. To help visualizing the concept, this behavior is described as precession of a 
magnetic dipole. In the absence of the rf radiation, the spin angular momentum precesses in the 
external magnetic field. The rf radiation with proper frequency is absorbed by the spin, which 
makes a transition to a higher energy state. The re-emitted electromagnetic radiation from the 
spin while it is relaxing back to the original state forms a detectable Nuclear Magnetic Resonance 
(NMR) signal (Free Induction Decay, FID), which is a characteristic of the static magnetic field, 
the chemical environment of the nuclei, and magnetic properties of the nuclei. NMR spectroscopy 
has wide applications in physics, biology, chemistry, etc. Although X-ray crystallography is the 
dominant method in protein structure determination, NMR spectroscopy has made drastic 
improvements and is used widely in structure determination of biomolecules. NMR spectroscopy 
provides information on a wide range of time scale dynamics thus, it is powerful in studying 
protein-protein and protein-ligand interactions, small molecule screenings, and optimization in 





When studying samples in solution, the rapid tumbling of the molecules will give rise to a 
high resolution NMR spectra. In these cases, the orientationally dependent anisotropic 
interactions are averaged out on NMR experiment time scale. However, in samples where 
anisotropic interactions cannot be neglected, such as large proteins or solid samples, 
considerations should be taken into account. In such cases Solid-State NMR spectroscopy 
(SSNMR) is used to overcome the loss of resolution in the spectrum of solid samples, which is 
due to line broadening effect of anisotropic interactions. SSNMR spectroscopy is a very useful 
technique in studying membrane proteins, which are not naturally soluble in aqueous solution and 
resistant to crystallization. In this study, we focus of solution NMR spectroscopy and we apply it 
to determine protein-ligand interactions. 
We studied the anti-cancer molecule, SHetA2, and its interaction with the heat shock 
protein 70 family member, mortalin, using computational and experimental methods. Our 
findings inspired us to design several SHetA2 analogs in attempt to optimize properties of 
SHetA2. Several oxygen and nitrogen containing analogs have been tested in vitro and by 
computational tools and showed promising results. 
Chapter II. NMR Spectroscopy and its Application in Protein-Ligand Binding Studies 
In chapter II, we first review the basics of NMR Spectroscopy. We briefly review other available 
methods in studying the protein-ligand complexes. NMR spectroscopy applications in studying 
protein-ligand interactions is reviewed next.  
Chapter III. Molecular Modeling Studies of Protein-Ligand Complexes 
We review the application of molecular modeling techniques in studying the protein-ligand 
interactions in chapter III, with the emphasize on Molecular Docking tool, Autodock, and 




Chapter IV. SHetA2 and mortalin Interaction 
In chapter IV we review the evolution of heteroarotinoids, and their biological activities with the 
emphasis on SHeA2 and its chemopreventive role. Mortalin, a receptor for SHetA2 ligand, p53 
protein, and p53-mortalin interaction is also reviewed. 
Chapter V. NMR Studies of the Interaction between mortalin and SHetA2 
This chapter includes our solution state NMR studies on the substrate binding domain of mortalin 
in complex with SHetA2 which helped identifying the binding site of SHetA2 on mortalin. The 
residues forming the hydrophobic binding pocket have been identified from the chemical shift 
perturbation data. 
Chapter VI. SHetA2 Molecular Modeling Studies of Mortalin-SHetA2 using GROMACS 
Chapter VI covers molecular docking (using Autodock) and molecular dynamic studies (using 
GROMACS) of SHetA2-mortalin and mutant V482F. Binding configuration and binding free 
energy has been calculated. We showed that residue V482 participates in the interaction of 
mortalin with SHetA2. V482F reduced the available space for binding of SHetA2 and changed 
the configuration of the ligand in the binding pocket.  
Chapter VII. Oxygen-Containing Analogs of the Flex-Het anticancer Agent SHetA2  
As our results from molecular mechanics studies suggests, hydrophobicity of the ligand is an 
important factor in its binding performance. Thus, we propose several analogs for SHetA2 and 
investigated the effect of hydrophobicity on their efficacy and potency. Chapter VII contains our 
published work on the activity of these oxygen-containing analogs of the SHetA2. 




Including a nitrogen atom in the structure of SHetA2 is proposed with the goal to increase the 
binding capacity of the molecule to its protein-binding partners. Chapter VIII is our work on 
nitrogen containing Flex-Hets and evaluating their activities. Several analogs have been tested 
and their free binding affinity, potency and efficacy values have been found and compared with 






NMR SPECTROSCOPY AND ITS APPLICATION IN PROTEIN-LIGAND BINDING 
STUDIES 
2.1. Introduction 
The first applications of NMR spectroscopy trace back to observing the resonance 
spectrum of paraffin (solid phase) by Bloch et al. [1] and water (liquid phase) by Purcell et al. [2] 
in 1946. Bloch and Purcell shared the Nobel Prize in Physics for discovery of NMR spectroscopy 
in 1952. Varian built the first commercial NMR spectrometer and the first NMR based 3D 
structure of a 57 residue protein was identified in 1985 by Wüthrich [3]. Since its discovery, 
improvements in software, hardware, and NMR techniques has broadened the applications of 
NMR spectroscopy. Some major breakthroughs include development of Fourier Transform NMR 
spectroscopy (by Ernst and Anderson), development of multidimensional NMR spectroscopy (by 
Jeener), and using solvent signal suppression that allows the protein spectra to be acquired in 
solution. A more recent improvement is development of the cryogenic probes with much higher 
sensitivities and higher signal to noise ratio that has lowered the protein concentration 
requirement to 0.5 mM.  
Improvements in powerful magnets with better field strength, homogeneity, and stability, 
together with the use of pulsed rf excitations instead of the traditional continuous wave scan, 
isotopic labelling techniques, and line narrowing techniques in solid state NMR, etc. have made 





NMR spectroscopy allows the studying of time-dependent chemical phenomena e.g. 
reaction kinetics and intramolecular dynamics. It provides information on proteins in more native 
aqueous environment, where molecules can tumble freely. Thus, NMR spectroscopy is the 
premier method in studying flexible proteins and intrinsically unfolded proteins. It can be used to 
study protein-folding intermediates and conformation changes. NMR spectroscopy can also be 
applied to variety of solid form samples such as powder, frozen samples, micro-crystals, 
proteoliposome, or gels. Protein-protein and protein-ligand interactions can be studied via NMR 
spectroscopy. Which makes it a powerful tool for drug screening and optimization studies. Very 
weak interactions (KD~1 mM), where protein-protein or protein-ligand complexes cannot even be 
isolated, can be detected by solution NMR. Not only the overall molecular tumbling but also the 
internal motions of the structural segments can be characterized by solution NMR spectroscopy. 
NMR spectroscopy obtains high-resolution structures. In solution state the directionally 
dependent anisotropic interactions are averaged and can be neglected on NMR experiment time 
scale, the rapid tumbling of the molecules will give rise to a high resolution NMR spectra. 
However, in large or solid samples where anisotropic interactions cannot be averaged out, Solid 
State NMR spectroscopy (SSNMR) is used to overcome the loss of resolution in the spectrum due 
to line broadening effect of anisotropic interactions. SSNMR is a very useful technique in 
studying membrane proteins, which are not naturally soluble in aqueous solution and resist to 
crystallization. In this study, we focus of solution state NMR spectroscopy and utilize it to 
investigate the interaction between protein and ligand. 
Protein-ligand binding is important in signal transmission, cellular metabolism, etc. Study 
of protein-ligand interactions is essential for understanding the regulation of biological functions 
and for designing more potent bioactive molecules that can inhibit proteins, modulate their 




biological functions are interaction of hormone receptors with hormones, enzyme inhibitor 
interactions, interaction of proteins with nucleic acid sequences, and antigen interaction with 
receptors. One important step in identifying and optimizing a drug candidate is identifying 
compounds with reasonable binding activities to specific protein receptors. Initially a very large 
number of compounds is screened and the leads are identified. NMR spectroscopy is a powerful 
tool in identifying the binding activity of leads/ligands with protein receptors to assess and 
identify drug candidates. 
In this chapter, we first review the basics NMR Spectroscopy. Then other available 
methods in studying protein-ligand complexes are briefly reviewed. Followed by introducing 
NMR spectroscopy applications in identifying protein-ligand interactions. 
 
2.2. Other Available Methods for Studying Protein-Ligand Interactions 
X-ray crystallography, NMR spectroscopy and 3D electron microscopy (3DEM) are the 
three main techniques used to determine the three-dimensional structures of macromolecules at 
atomic resolution. The first one-dimensional protein spectrum was recorded about four decades 
ago. To date (January 2019) 12485 protein structures has been release from NMR experiments. 
While 132182 structures have been released from X-ray Crystallography experiments and 2746 
structures from 3D electron microscopy [https://www.rcsb.org/]. 
In X-ray crystallography, purified and crystalized protein is subjected to X-ray beams and 
diffracts the beam into characteristic diffraction pattern. This diffraction pattern is then analyzed 
to determine the distribution of electrons in the protein sample. From this map of electron density, 
the location of each atom will be determined. The quality of the crystals is the determining factor 
in accuracy of the predicted atomic structure. While X-ray crystallography provides very detailed 




makes the study of the flexible proteins difficult. Flexible parts can be invisible in electron 
density maps.  
Femtosecond crystallography using X-ray Free Electron Lasers (XFEL) is 
revolutionizing the X-ray crystallography. In this method a stream of crystals (nanometers to 
micrometers size) passes through a beam of extremely short (femtosecond long) and intense 
pulses (up to 1013 photons) created by the XFEL. Each X-ray pulse produces a diffraction pattern 
from a crystal. Tens to hundreds of thousands of snapshot diffraction patterns will be created. 
This powerful method allows study of molecular processes that happen over very short time, e.g. 
absorption of light by biological chromophores. Conventional sources of beams can break the 
bonds and change the structure during exposure. XFEL however outruns the radiation damage.  
In electron microscopy a high energy electron beam bombards the sample. Electron 
lenses are used to provide an image from the scattering pattern electrons. The most commonly 
used technique to get a 3D structure from 2D projection image is Cryo-EM. In this method, thin 
films of samples preserved on none-crystalline ice are placed on the electron microscopy grid and 
thousands of 2D images capture the molecule in different orientations. Then a computational 
approach is used to obtain a 3D mass density map. An atomic model of the macromolecule then is 
fitted into 3DEM maps.  
Under cryogenic temperatures, the biological sample rapidly freezes in its aqueous 
environment thus sample damage due to the electron irradiation reduces, making it possible to use 
higher doses of electrons to increase the signal to noise ratio. This also avoids ultrastructure 
changes and redistribution of elements. Moreover, the structure is similar to the native or liquid 
state. Molecules are in solution and are not distorted by being attached or flattened against the 




lipids is distinguishable. Thus, Cryo-EM makes it possible to study the dynamics of biological 
macromolecular structures in near native condition at close to atomic resolution. 
Single particle 3DEM is used to study structures at resolution limits comparable to 
macromolecular crystallography and can be used to visualize amino acid sidechains, surface 
water molecules, and bound ligands. Cryo-electron tomography (CET) yields slightly lower 
resolution structural information such as protein domains and secondary structures.  
Some disadvantages of this technique include low image contrast and signal to noise ratio 
due to very low electron absorption of biological macromolecules. Difficulty in obtaining good 
images due to the thick ice cross section of a tilted frozen sample, and the need to keep samples at 
temperatures below 135 degree Celsius. 
NMR spectroscopy studies the behavior of nuclear spin angular momentum. The rf 
radiation provides sufficient energy for the nuclei to resonance. The re-emitted electromagnetic 
radiation from the nuclei while the nuclei spin is relaxing back to original state forms a detectable 
NMR signal. The NMR spectrum is a signature of a target molecule and it gives us information 
about nuclei type, concentration, chemical environment, and molecule structure and dynamics. 
NMR spectroscopy provides information on a wide range of time scale dynamics thus is powerful 
in determining protein-ligand interactions, small molecule screenings, and optimization in drug 
discovery and development. It provides easier study of protein-protein interactions when co-
crystallization of the complex is difficult. Sample preparation is easier and more flexible in NMR 
spectroscopy. Solid State NMR spectroscopy is a very useful technique in studying membrane 
proteins, which are not naturally soluble in aqueous solution and difficult to crystallize.  
X-ray and electron microscopy are based on Fourier optics and image reconstruction 
from diffraction data. NMR spectroscopy however is based on measuring structural restraints 




Studying the protein complexes via X-ray crystallography and NMR spectroscopy is hindered by 
the limitations of these methods. Integrative or Hybrid Methods (I/HM) are very useful and fast 
growing ways of studying large macromolecular assemblies such as ribosomes complexes, tRNA 
and protein factors and muscle actomysins, membrane proteins, membrane embedded ion 
channels and receptors. 3DEM, Transmission Electron Microscopy (TEM) and cryo-TEM ,NMR 
spectroscopy, X-ray crystallography, mass spectroscopy, chemical cross linking, fluorescence 
resonance energy transfer, and computational methods can be combined to study very large 
macromolecular assemblies. 
 
2.3. Theory of NMR Spectroscopy 
The theory of NMR includes quantum mechanics of nuclear spin angular momentum, 
denoted by I. The magnitude of this vector quantity is given by 
 |𝐈| = [𝐈 ⋅ 𝐈] / = ħ[I(I + 1)] /  (2.1) 
Where I is the nuclear spin angular momentum quantum number and ħ is the Planck’s constant 
divided by 2π. 
Nuclei with even mass number and even atomic number thus zero spin quantum number, 
are NMR inactive. These nuclei are not affected by external magnetic field. Nuclei with even 
mass numbers and odd atomic numbers have integral spin numbers (I = 1, 2, 3, …) and those with 
odd mass number, regardless of atomic number being odd/even, have half–integral spin numbers 
(I = 1/2, 3/2, 5/2, …). These nuclei are affected by external magnetic field thus are NMR active. 
Based on principles of quantum mechanics only one Cartesian component of I can be 





 I = ħm (2.2) 
Where m is the magnetic momentum quantum number and takes 2I+1 values from –I to I thus 
m=(-I, -I+1 … I-1, I). For a nucleus with quantum spin number I the number of possible spin 
states is given by m = 2I+1. Thus, z-component of I takes discrete values, meaning the orientation 
of the spin angular momentum vector is quantized. In the absence of an external magnetic field 
the quantum states corresponding to all 2I+1 values of m, have same energy values and there is 
no preferred orientation. The isotopes of interest in this study are spin ½  nuclei, 1H, 13C and 15N 
which have two allowed spin states, m = ±1/2. 
Nuclei also have nuclear magnetic momentum μ, defined by:  
  𝛍 = γ𝐈 
μ = γℏ I(I + 1) 
 
(2.3) 
 μ =  γI = γħm (2.4) 
Where γ is the gyromagnetic ratio, a characteristic constant of a given nucleus related to the 
receptivity (sensitivity) of a nucleus in NMR spectroscopy. Some of the properties of the most 
commonly used nuclei in biological NMR spectroscopy, including the gyromagnetic ratio are 
listed in table 2.1. 
Nuclear magnetic moment is quantized. From the equation 2.1 it is perceivable that the 
nuclei with the same quantum number I have the same spin angular momentum. However, the 














1H ½ 26.752 99.99 
2H 1 4.107 0.012 
13C ½ 6.728 1.07 
14N 1 1.934 99.63 
15N ½ -2.713 0.37 
17O 5/2 -3.628 0.038 
19F ½ 25.18 100 
23Na 3/2 7.081 100 
31P ½ 10.839 100 
113Cd ½ -5.961 12.22 
 
Natural abundance of proton and its large gyromagnetic ratio has made it the most popular spin 
studied in NMR spectroscopy. 
 
2.3.1. Energy States and Boltzmann Distribution 
Energy of the spin states of the nucleus in presence of an external magnetic field B with 
the strength equal to B0 is given by: 
 𝐄 = −𝛍 ⋅ 𝐁 (2.5) 




By convention, the external magnetic field is applied along z-axis of laboratory 
coordinate system. From the equation 2.6 it is understood that the energy is quantized and takes 
discrete values. In the presence of an external static magnetic field, 2I+1 equally spaced energy 
levels, known as Zeeman levels, exist (Figure 2.1). By applying electromagnetic radiation, 
transitions between Zeeman states can be stimulated. According to the selection rule, only 
transition between two Zeeman states with ∆m = ±1 is allowed. The required energy to stimulate 
a transition is then: 
 ∆E = ℏγB  (2.7) 
According to Plank’s law the transition frequency, i.e. the frequency of electromagnetic radiation 






= γB  
(2.8) 











When a spin ½ nucleus is placed in an external magnetic field (B0), the nuclear magnetic moment 
experiences a torque trying to align it to the field. Nuclei in spin state m = +1/2 are in the lower 
energy state (–state (E1)) and align parallel to the field, and those in the negative spin state m = -





Figure 2.1 Zeeman splitting for a spin ½ nucleus. 
 
The sensitivity of NMR spectroscopy depends on the population difference between Zeeman 
transition states. At equilibrium, the lower energy states are more populated. The relative 

















)/(2I + 1) 
(2.11) 
Where N is the total population of the spins from which Nm nuclei are in the mth state, kB is the 
Boltzmann constant and T is the absolute temperature in Kelvin. The population of states depends 
on both nucleus type and the external magnetic field strength. In thermodynamic equilibrium, the 
populations of nuclei in each energy state are nearly equal and the nuclei in parallel state (lower 
energy) slightly more. By increasing the external magnetic field strength, the energy differences 




magnetic field, the population difference is in the order of 1 in 105 and only a small fraction of the 
spins contributes to the signal intensity. This characterizes NMR as an insensitive spectroscopic 
technique and emphasizes the necessity of having stronger magnets.  
 
2.3.2. The Bloch Equations 
The Bloch equations formulate a semiclassical vector model to describe a sample of 
nuclei and how the sample/bulk magnetic moment (M) evolves with time in the static external 
magnetic field; M(t). 
Vector sum of the magnetic moment μ and angular momentum I over all the nuclei, give the 
macroscopic magnetic momentum M and angular momentum J for the sample. 
 M =  N (2.12) 
Where N is the small population difference of spins between the higher and lower energy spin 
states. 
At the thermal equilibrium sum of the transverse components thus the net moment in the 
x–y plane is zero and M is parallel to the external magnetic field, i.e. M=M0k. The magnetic 
moment of a nucleus precesses at an angle  around the z–axis, and the frequency of the 
precession is the Larmor frequency. If the nuclei is now in an external magnetic field, the torque 
on the sample/bulk magnetic moment, M(t), will be: 
 d𝐉(t)
dt
= 𝐌(t) × 𝐁(t) 
(2.13) 






= 𝐌(t) × γ𝐁(t) 
(2.14) 
Now we re-write the above equation in a rotating reference with an angular velocity of ω with 






+ 𝐌(t) × ω 
= 𝐌(t) × (γ𝐁(t) + ω) 
(2.15) 
If we define the effective field, Beff as: 
 𝐁 = 𝐁(t) + ω/γ (2.16) 
The equations of motion for magnetization in the rotating frame is going to have the same form as 
in laboratory frame. For ω = -γB(t), the effective field Beff is 0 thus  
𝐌( )
= 0 which means that 
𝐌(𝑡)  is time independent in the rotating frame and precesses around B(t) with a constant 
frequency ω = -γB in laboratory frame. For a static external field with the strength of B0, ω0 = -
γB0. ω0 is known as Larmour frequency or precessional frequency and is same as the magnitude 
of the transition frequency between Zeeman levels. 
By convention, γB is referred to as the magnetic field strength in unit of frequency (s-1 or 
Hertz) instead of B with units of Gauss or Tesla, e.g. spectrometers with an 11.7 T and 21.2 T 
magnet are called 500 MHz and 900 MHz respectively.  
As mentioned earlier, in thermal equilibrium the bulk magnetization is parallel to the 
external magnetic field. Radiofrequency (rf) electromagnetic radiation which can be applied in 
the form of pulses with duration of several microseconds, can disturb the equilibrium of the bulk 
magnetization from its parallel position. Once the bulk magnetization is displaced from the 




a time-varying magnetic field, which according to Faraday’s induction law induces a detectable 
electromotive force (emf), i.e. a signal in a coil.  
The linearly polarized rf field along the x-axis can be decomposed into two circularly polarized 
field rotating in opposite directions about the z-axis (Figure 2.2). 
 𝐁 (t) = 2B cos(ω + ϕ) 𝐢 
= 𝐁 {cos(ω + ϕ)𝐢 + sin(ω + ϕ)𝐣}
+ 𝐁 {cos(ω + ϕ)𝐢 − sin(ω + ϕ)𝐣} 
(2.17) 
Where B1 is the amplitude of the applied field, ωrf is the angular frequency of the rf field known 
as carrier frequency or transmitter frequency, and ϕ is the phase of the field.  
 
 
Figure 2.2 The decomposition of radio frequency radiation  
into two circularly polarized fields rotating in opposite directions about the z axis. 
 
Since only the component of the field rotating in the same direction as the sample magnetic 
moment interacts significantly with the sample magnetic moment, the counter-rotating 




 𝐁 (t) = B {cos(ω + ϕ) 𝐢 + sin(ω + ϕ)𝐣} (2.18) 
We then can use the rotating frame transformation by moving to a rotating frame with angular 
frequency ωrf to solve the time-dependent field and obtain the following equation: 
 d𝐌 (t)
dt
= 𝐌 (t) × γ𝐁  
(2.19) 
Br is the effective field in the rotating frame and is given by: 
 𝐁 = B cos ϕ 𝐢 + B sin ϕ 𝐣 + Ω/γ 𝐤  (2.20) 
Ω = -γB0 – ωrf = ω0 - ωrf is the offset. If the carrier frequency ωrf is equal to the Larmor frequency 
ω0, then the offset will be 0. In this case the irradiation is called on-resonance and Br= B1. When 
on resonance, low–energy (parallel) nuclear spins get excited into higher energy levels. Followed 
by the transition of excited spins back to original energy levels, measureable current will be 
induced in the receiver coil that forms the NMR signal.   
 





The magnitude and the angle of the effective field with respect to the z-axis is: 













The Mr(t) precesses around the effective field Br with an angular frequency of 𝜔 = −𝛾𝐵 . 
On resonance, the bulk magnetization Mr(t) precesses around the B1 field with frequency ωr = -
γBr = -γB1 = ω1. Where 1 is the angular frequency of applied pulse. 
 
2.3.3. Relaxation 
As mentioned earlier, following the rf pulse, the sample magnetization precesses around 
the external magnetic field with frequency equal to Larmor frequency. Magnetization eventually 
decays and returns to the Boltzmann equilibrium distribution. There are two relaxation processes 
through which magnetization decays back to equilibrium. Longitudinal/spin-lattice relaxation and 
transverse/spin-spin relaxation. From Bloch equations, we obtain the relaxation terms as follows: 
 dM (t)
dt
= R [M − M (t)] 





= −R M /  







R1=1/T1 is the spin-lattice relaxation rate constant (T1 is the spin–lattice relaxation time), 
R2=1/T2 is the spin-spin relaxation rate constant (T2 is the spin–spin relaxation time).  
The energy absorbed from an applied rf electromagnetic field can be either dissipated to the 
lattice (T1 relaxation), or can be exchanged between spins of the system (T2 relaxation). 
T1 relaxation is the time required for the net magnetization to reach its equilibration state that 
allows the nuclear spins to dissipate their energy to the lattice. The net magnetization is restored 
along the z–axis and T1 relaxation is in the direction of static magnetization field, B0. Generally, 
an experiment is repeated after a period of 5T1 to allow enough time for the spins to fully recover 
the net magnetization, M0. 
Interactions between spins result in the loss of phase coherence in the x–y plane or 
transverse plane and is described by time constant, T2. T2 relaxation is in the transverse plane 
perpendicular to the static magnetization field and is the time required for the net magnetization 
in the transverse plane to dephase. Dephasing of the vectors results in an exponential decay of the 
net transverse magnetization. Thus T2 is a measure of how fast the transverse magnetizations (Mx 
or My) decays to zero. Spin–spin interactions arise from local magnetic field inhomogeneity due 
to an inhomogeneous B0 field from the spectrometer magnet or due to varying magnetic 
susceptibilities within the sample. Measuring T2 is an indicative of the nuclear environments in a 






Figure 2.4 Spin–spin relaxation  
modelled as decoherence of magnetization in the transverse plane due to local magnetic field 
inhomogeneity. 
Ideally, transverse relaxation is inversely proportional to the spectral linewidth. However due to 
the spin diphase in x-y plane, inhomogeneous local magnetic fields increase the decay rate.  
 LW1/ 2 =1/p T2 * (2.25) 
LW1/2 is the spectral peak width at half height, T2* is the relaxation value and has two 
components. One is the real T2 value of the sample and the other is contribution of field 
inhomogeneity. 
 1/T2* = 1/T2 + 1/Tinhom (2.26) 
Back to the Bloch equations, substituting , ,  from (2.23) and (2.24) into (2.14), Bloch 
equations can be written in the rotating reference frame. For convenience, we write the Bloch 




−R −Ω ω sin ϕ
Ω −R −ω cos ϕ
−ω sin ϕ ω cos ϕ −R














0 −Ω ω sin ϕ
Ω 0 −ω cos ϕ
−ω sin ϕ ω cos ϕ 0
𝐌(t)  
(2.28) 
If B1 and 𝜙 are time independent then the solution to this equation can be represented as a series 
of rotation matrices being applied on the magnetization M(0): 
 𝐌 τ = 𝐑 (ϕ)𝐑 (θ)𝐑 (α)𝐑 (−θ)𝐑 (−ϕ)𝐌(0) (2.29) 
𝐑 (𝛽)  represents a right handed rotation of angle β around i-axis. A positive rotation is a 
counterclockwise rotation viewed down the x-axis. 
This rotation matrix can be used to calculate the effect of rf pulses on isolated spins. 




0 cos β − sin β
0 sin β cos β
 
𝐑 (β) =
cos β 0 sin β
0 1 0
− sin β 0 cos β
 
𝐑 (β) =
cos β − sin β 0




Transverse sample magnetization results in the maximum NMR signal thus rf pulses that cause 
90° rotation of M(t) from the z-axis are of great importance in NMR spectroscopy. 
Let us assume rf pulse duration/pulse width is τp, pulse strength B1, tilt angle of the pulse θ = π/2 
is applied onto the equilibrium sample magnetization, M0 along the y-axis, thus phase ϕ = π/2. 












Where α is the rotation angle, α= -γBrτp. A maximum transverse magnetization can be generated 
with α = 90°. The corresponding rf pulse is called 90° or a π/2 pulse. A p/2 pulse rotates the net 
magnetic moment vector to the x–y (transverse) plane and equalizes the population of spin states 
for the spin ½ nuclei. 180° pulse or π pulse on the other hand generates no transvers 
magnetization, instead it inverts the sample magnetization to be –M0k, and the population in the 
two ±½ spin states. For a nucleus with a positive γ, a π pulse inverts the population such that –½ 
state (β-state) possesses excess population. After the rf pulse is applied, the sample magnetization 
precesses around the direction of the effective magnetic field in the rotating frame for a period of 
time called acquisition period, t during which a signal is generated by the precessing 
magnetization and recorded by the NMR spectrometer. This induced signal is an exponentially 
decaying function of time and is called free induction decay (FID). The FID is then Fourier 
transformed (FT) to the frequency domain to obtain the characteristic NMR spectrum. 
 
Figure 2.5 Fourier transformation of FID 





Bloch equations for the free induction decay in the rotating frame for a 90° pulse with Bx/y = 0 
and Bz = B0, give two components for M, Mx and My, which can be combined and be written as 
M+ as follows: 
 M (t) = M (t) + iM (t)
= M sin α cos(Ωt) e
+ M sin α sin(Ωt) e  
= M sin α e  
(2.32) 
As it is seen in the above equation the transverse components of the sample magnetization decay 
with a factor of e  in the spin-spin relaxation process. 
Both the real and imaginary parts of the complex signal are detected by the NMR spectrometer 
with an experimental proportional factor λ. This is a complex time-domain signal which can then 
be converted to a complex frequency-domain signal through Fourier transformation. Let us define 
s (t) = λM (t). Then:  
 
S(ω) = s (t)e dt
= λM
R
R + (Ω − ω)
+ i λM
Ω − ω
R + (Ω − ω)
 
= ν(ω) + iu(ω) 
 
(2.33) 
The real part, ν(ω) represents a signal with an absorptive Lorentzian lineshape and the imaginary 
part, u(ω) represents a signal with dispersive Lorentzian lineshape. Normally the real part of the 






Linewidth of the Lorentzian lineshape ν(ω),  Δν , is defined as full-width at half 
maximum and can be shown to be Δν =
∗
=  . R  in the homogeneous part of 
the linewidth is due to intrinsic molecular properties and R  in the inhomogeneous part of the 
linewidth can be due to instrumental imperfections. Homogenous linewidth is proportional to the 
rotational correlation time of the protein, thus to the molecular mass and shape of the protein. If 
the linewidth is significantly larger than expected, this can imply that aggregation is increasing or 
that chemical exchange effects are contributing to the linewidth. 
 
2.3.5. Chemical Shift 
The static external magnetic field induces motion of electrons which then generates local 
secondary magnetic fields. So the net magnetization is sum of both static external magnetic field 
and local secondary magnetic fields (The latter is called nuclear shielding). The observed 
resonance frequencies are not the same for all nuclei, instead they depend on the local electronic 
and structural environment of each individual nucleus. The differences in resonance frequencies 
for different nuclei is called chemical shifts.  
 B = (1 − σ)B  (2.34) 
For convenience and because it is difficult to measure absolute value of the chemical shift of a 
resonance, chemical shifts are measured in parts per million (ppm) relative to a reference 
resonance signal. 









× 10 = (σ − σ) × 10  
(2.35) 
Ω  and Ω are the offset frequencies of the reference signal and the signal of interest. Chemical 
shifts in the unit of ppm are independent of the static magnetic field strength. Average chemical 
shifts of nuclei in amino acids of proteins (in ppm) is listed in Table 2.2.  
 
Table 2.2 Average chemical shifts of nuclei in amino acids of proteins (in ppm)[4]. 
Residue 1HN 15N 13C 13Cα 1Hα 1Hβ 
Ala 8.15 122.5 177.6 52.2 4.33 1.39 
Arg 8.27 120.8 176.6 56.0 4.35 1.89, 1.79 
Asn 8.38 119.5 175.6 52.7 4.74 2.83, 2.75 
Asp 8.37 120.6 176.8 53.9 4.71 2.84, 2.75 
Cys 8.23 118.0 174.6 56.8 4.54 3.28, 2.96 
Gln 8.27 120.3 175.6 56.0 4.33 2.13, 2.01 
Glu 8.36 121.3 176.6 56.3 4.33 2.09,1.97 
Gly 8.29 108.9 173.6 45.0 3.96 . 
His 8.28 119.1 174.9 55.5 4.60 3.26, 3.20 
Ile 8.21 123.2 176.5 61.2 4.17 1.90 
Leu 8.23 121.8 176.9 55.0 4.32 1.65 
Lys 8.25 121.5 176.5 56.4 4.33 1.85, 1.76 
Met 8.29 120.5 176.3 55.2 4.48 2.15, 2.01 
Phe 8.30 120.9 175.9 57.9 4.63 3.22, 2.99 
Pro . 128.1 176.0 63.0 4.42 2.28, 2.02 
Ser 8.31 116.7 174.4 58.1 4.47 3.88 
Thr 8.24 114.2 174.8 62.0 4.35 4.22 
Trp 8.18 120.5 173.6 57.6 4.66 3.32, 3.19 
Tyr 8.28 122.0 175.9 58.0 4.55 3.13, 2.92 
Val 8.19 121.1 176.0 62.2 4.12 2.13 
 
In an anisotropic electronic charge distribution (which is true in most cases), the effect of nuclear 




. In the principle 
coordinate system the shielding tensor is a diagonal matrix with components σxx, σyy, σzz.  
Chemical shifts in protein NMR spectroscopy consist of the random coil chemical shift 




chemical shift component. Secondary chemical shifts are useful in prediction the protein structure 
and have information regarding the secondary and tertiary structure of the protein. 
 
2.3.6. Limitations of the Bloch Equations 
The splitting of the resonance signals is observed in high resolution NMR spectra of 
liquids. Direct dipolar interactions through space between magnetic dipole moments, dipolar 
coupling, is an anisotropic quantity that in solutions averages out to zero. Thus, it cannot explain 
the splitting of signals in NMR spectra of solutions.  Spin-spin coupling or scalar coupling 
however can explain the splitting of the resonance signals. Scalar coupling is indirect dipole-
dipole interaction between the two spins mediated by bonding electrons and is orientation 
dependent. As the number of bonds separating the nuclei increases, the strength of scalar coupling 
decreases. The interaction between the nuclei is measured by nJab, scalar coupling constant, 
which has the units of Hertz. n is the number of covalent bonds separating the two nuclei a, b.  
The three-bond scalar coupling constant 3J has a relationship with the dihedral angle and is a 
quantitative method to obtain dihedral angles in NMR spectroscopy via Karplus equation: 
 J = Acos φ + Bcosφ + C (2.36) 
φ is the dihedral angle and A, B, C are constants 
Let us consider a sample of two spin ½ nuclei. We show the spins by I and S. with the 
resonance frequencies ωI and ωS. 
 ω = −γ B (1 − σ ) (2.37) 





























































































The transition between states obeys the selection rule Δm = ±1. Thus only transitions between 
states 1-2, 1-3, 2-4 and 3-4 can happen, with the energy differences between these transitions to 
be: 
 |E − E | =  ℏω , |E − E | = ℏω , 





In the absence of scalar coupling, the transition frequency between energy states 1-2 and 3-4 is 
ωS, and the transition frequency between energy states 1-3 and 2-4 is ωI. So two resonance lines 
are predicted. 
In the presence of the scalar coupling between spins I and S however: 













































The transitions still obey the selection rules thus only the transitions between energy states 1-2, 1-
3, 3-4, 2-4 can happen with the following resonance frequencies: 
 𝜔 = 𝜔 + 𝜋𝐽 , 𝜔 = 𝜔 + 𝜋𝐽 , 𝜔 = 𝜔 − 𝜋𝐽 , 𝜔
= 𝜔 − 𝜋𝐽  
(2.45) 
Thus, four resonance spectral lines are predicted as it is observed in practice. Bloch equations fail 






2.3.7. Quantum Mechanical Representation of NMR Spectroscopy  
Quantum mechanics provides a thorough approach to analyze the dynamics of the nuclear 
spin system via density matrix formulation. In Bloch equations, the evolution of magnetization 
vector was observed. And as it was mentioned, this approach has limitations when it comes to 
coupled/interactive nuclei. In the quantum mechanical approach, however the evolution of the 
density matrix is studied and gives a more complete description of the spin system over time. 








Ĥ is the Hamiltonian of the system, Ψ(t) is the wavefunction of the system and has all the 
information about the state of the sytem. Knowing the wave function all the observable properties 
of the system can be determined. Using the separation of variables, for a time-independent 
Hamiltonian, the Schrodinger equation can be solved. 
 
Ψ(t) = ψ(τ)e ħ
 
= ψ(τ)e  
(2.47) 
Where E=ħω and Ψ(τ) contain the time dependent spatial and spin variables. 
Expectation value of a property A is the average magnitude of A and is obtained from the integral 
of wave function as follows: 
 
〈A〉 = Ψ∗(t)AΨ(t) dτ 
(2.48) 
For a spin ½ system in the static magnetic field, the wavefunction can be written as the linear 




 Ψ = c ψ + c ψ = ae ψ + be ψ  (2.49) 
ψ  and ψ  are the two states, Eα and Eβ are the energy of the states, and a = |a|eiϕa, b = |b| eiϕb are 
complex numbers which satisfy the normalization equation |a|2 + |b|2 = 1. 
The expected values are going to be: 
 
〈μ 〉 = Ψ∗μ Ψdτ = γℏ|a||b| cos(ω + ϕ) 
(2.50) 
 
 〈μ 〉 = Ψ∗μ Ψdτ =  γℏ|a||b| sin(ω + ϕ) 
(2.51) 
 
〈μ 〉 = Ψ∗μ Ψdτ =  
γℏ
2
(|a| − |b| ) 
(2.52) 
where ω0= ωα - ωβ= -γB0 is the Larmor frequency and ϕ= ϕα - ϕβ is a phase angle.  
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2.3.8. The Density Matrix 
The density matrix formulation of quantum mechanics facilitates the calculations on 
commonly used quantum mechanical operators like scalar products and expectation values. A 
further simplification is using a notational system called Dirac Notation. In Dirac notation, the 
wave function and its conjugate are shown by |ψ⟩ and ⟨ψ| and the scalar product is shown by 
⟨φ|ψ⟩. The expectation value is written as ⟨A⟩ = ⟨ψ|A|ψ⟩ . 
Using |α⟩ and |β⟩ basis functions to represent the states of spin in a spin ½ nucleus, 





 are eigen vectors, the matrices of the angular momentum operators 



















Which satisfy the commutation relation of: 
 𝐼 , 𝐼 = 𝑖𝐼 , 𝐼 , 𝐼 = 𝑖𝐼 , [𝐼 , 𝐼 ] = 𝑖𝐼  (2.55) 
An arbitrary ket can then be shown by a linear combination of the eigen kets and eigen bras: 




A pulse sequence consists of rf pulses (shown by time dependent Hamiltonian) and 
delays (shown by time independent Hamiltonian). Let us neglect the interaction between the spin 
system and the lattice. Equivalent to the rotating frame transformation in Bloch model, here we 




Consider a spin ½ nucleus in the static external magnetic field B0. If a linearly polarized rf pulse 
is applied with the magnitude of 2B1 and angular frequency of ωrf, The Hamiltonian has two 
terms, the Zeeman Hamiltonian and the rf pulse Hamiltonian terms: 
 H =  −𝛍. 𝐁(t) = H + H  
= ω I +  ω [I cos(ω t + ϕ) + I sin (ω t + ϕ)] 
(2.57) 
Where ω = −γ B  and ω = −γ B  
Using the transformation matrix U=exp (iωrfIzt), and after some calculations we get the time 
independent Hamiltonian as 
 𝐇 = ΩI +  ω [I cos(ϕ) + I sin (ϕ)] (2.58) 
The solution of this Hamiltonian describes how the density operator evolves in the rotating frame.  
We define the exponential rotation operators as: 
 𝐑 (α) = e  (2.59) 
Then for a rf pulse with duration of τp, α=ω1 τp , and rotation of the initial magnetization σ(0) is 
 σ(t) = 𝐑 (α)σ(0)𝐑 (α) (2.60) 
Where 𝐑 (α) and 𝐑 (α) are pulse rotation operators.  
After expansion of 𝐑 (α) and using the Pauli spin matrices we get: 











 𝐑 (α) = c is
is c




 𝐑 (α) =
c s
−s c




 𝐑 (α) = c + is 0
0 c − is
, 𝐑 (α) =
c − is 0
0 c + is
 (2.64) 
 
Where c = cos(α/2), s = sin(α/2). 
Now we consider the simplest NMR experiment, which is a single pulse experiment. For an x-
phase pulse with rotation of angle α, applied on Iz: 
 



















c − s 2ics




cos α i sin α
−i sin α − cos α
= I  cosα − I  sinα 
(2.65) 
For α=180° and α=90°, we will get: 
 





= −I  
(2.66) 
This is compatible with the result from Bloch model and shows that this pulse rotates the 













= −I  
(2.67) 
Which is again compatible with the Bloch model showing the change of magnetization from + z 
direction to –y axis followed by the precession of the −I  magnetization under the time 




 𝐇 = (ω − ω )I = ΩI  (2.68) 
 σ(t) = −e I e = I sin(Ωt) − I cos(Ωt) (2.69) 
σ(t) changes from – Iy at t = 0 to +Ix at Ωt = π/2.  
 
2.3.9. Multi Spin Systems 
The density operator applications can be extended to coupled spin systems where the 
Bloch model fails. Wave functions and operators are shown with higher dimension matrices. The 
spin systems can consist of N spin in general but we first look at a two spin ½ system of spins I 
and S. The system rotation is derived by applying the rotation operator on each individual spin 
and then multiplying the results. 






c 0 −is 0
0 c 0 −is
−is 0 c 0
0 −is 0 c
 
(2.70) 






c −is 0 0
−is c 0 0
0 0 c −is
0 0 −is c
 
(2.71) 
Multiplying the results, we get: 
 
𝐑 (α) = 𝐑 (α)[I]𝐑 (α)[S] =
c icsu icsv −s
icsu 1 − s u −s uv icsu
icsv −s uv 1 − s v icsv








c −icsu −icsv −s
−icsu 1 − s u −s uv −icsu
−icsv −s uv 1 − s v −icsv
−s −icsu −icsv c
 
(2.73) 
Where u = cosθ + sinθ, v = cosθ – sinθ and c = cos(α/2), s = sin(α/2). 
This approach is useful in heteronuclear NMR experiments. 
Now we apply the following approach to a two spin system after applying a single pulse. 
The equilibrium matrix representation of the density operator for a two weakly coupled spin 
system is: 




ω + ω 0 0 0
0 ω − ω 0 0
0 0 −ω + ω 0
0 0 0 −ω − ω
 
(2.74)  
A x-pulse with rotating angle of α=π/2 (for simplicity) rotates the initial density operator. 
 𝐑 =
1 −i −i −1
−i 1 −1 −i
−i −1 1 −i
−1 −i −i 1
, 𝐑 =
1 −i −i −1
−i 1 −1 −i
−i −1 1 −i
−1 −i −i 1
 
and  σ(0) =
ω + ω 0 0 0
0 ω − ω 0 0
0 0 −ω + ω 0
0 0 0 −ω − ω
 
Thus 







= −ω I − ω S  
(2.75) 




Considering the coupling constant JIS, the matrix representation of the exponential operator will 
be: 
 exp [i(ΩIIz+ΩSSz+2πJISIzSz)t] = 
i
2
0 0 0 −e ( ) − e ( )
0 e ( ) e ( ) 0
0 e ( ) e ( ) 0
0 0 0 e ( ) + e ( )
 
(2.76) 
The spectrum has two doublets, total of four signals with the frequencies equal to ΩI±πJIS and 
ΩS±πJIS. This observed magnetization comes from the fact that the trace of the above matrix has 
four terms exp[i(ΩI+πJIS)t], exp[i(ΩI-πJIS)t], exp[i(ΩS+πJIS)t], exp[i(ΩS-πJIS)t].  
 
2.4. Application of NMR Spectroscopy in Protein-Ligand Interactions 
Study of the dynamics processes of protein-ligand interaction can improve our 
understanding of their mechanism. E.g. Kinetic and thermodynamic parameters, dissociation 
constants and conformational changes. Surface plasmon resonance, isothermal titration 
calorimetry, circular dichroism, fluorescence polarization assay, fluorescence resonance energy 
transfer, quartz crystal microbalance, ultra/visible absorption spectroscopy, enzyme linked 
immunosorbent assay, differential scanning fluorimetry, analytical ultracentrifugation, microscale 
thermophoresis, small angle X-ray scattering, atomic force microscopy, electron ionization mass 
spectroscopy, and NMR spectroscopy are some of the methods used to study protein-ligand 
interactions.  
NMR spectroscopy provides site-specific quantitative information and is the most 
powerful technique among the above mentioned techniques for investigating the dynamics of the 
protein-ligand interactions [5]. NMR approaches can be applied either in fast exchange, or in 




observable quantities of the free and bound states of receptor or ligand and includes population 
averaging of chemical shift, longitudinal relaxation rate R1, and transverse relaxation rate R2. This 
method is suitable for studying very weak binding. The second category of NMR experiments 
uses the relaxation dispersion experiment or ZZ-Exchange spectroscopy to analyze micromolar or 
sub-micromolar dissociation constant and not very weak interactions. Appropriate approach 
should be chosen according to the chemical shift regime [6]. 















 k = [B]k + k   (2.79) 
A, is the protein, B is the ligand, A:B is the complex. kon and koff are association and dissociation 
rates. KD is the dissociation constant. KD <0.1 μM is considered strong interactions and KD >10 
μM is considered weak. k  is the exchange rate in units of s-1 and varies by changing the 
concentration. k  and Δω (the chemical shift difference between the free and bound states), 
identify the chemical exchange regime of the interaction. If kex ≫Δω the interaction is considered 
in the fast exchange regime, if kex ≪Δω the interaction is considered in the slow exchange regime, 






Figure 2.6 NMR methods 
for quantitative analysis of protein-ligand interactions with their chemical shift timescales [6]. 
  
Transferred R1, transferred R2, chemical shift titration, saturation transfer difference 
(STD) and water-ligand observed via gradient spectroscopy (Water-LOGSY) are methods used in 
the fast exchange regime. 
In transferred R1 method, relative changes in the R1 relaxation rate of a ligand is 
measured in free and bound state. And the longitudinal relaxation rate R1av is measured by 
population-averaging the free and bound states: 
 𝑅 = 𝜌 𝑅 + 𝜌 𝑅  (2.80) 
Transferred R2 is similar to transferred R1 method but more sensitive and is applied only when the 
interaction is sufficiently fast. 
In the fast exchange regime, saturation transfer difference (STD) and water-ligand observed via 
gradient spectroscopy (Water-LOGSY) are the most commonly NMR methods used to 
quantitatively analyze protein-ligand interactions. Because in these methods the resonance signals 




Some other major ligand-observed NMR methods are transferred-NOE spectroscopy (NOESY), 
transient transferred NOE spectroscopy, and cross saturation [7, 8]. 
In the ligand-observed approach, a spectrum of free ligand is acquired and then the 
protein is added. In protein-observed approach, the spectrum of the free protein is obtained and 
then the ligand is titrated into the protein sample. These two approaches are complementary and 
ideally, use of both together gives a complete picture of the binding. 
Although in theory all NMR spectroscopic parameters can be used as measures of 
protein-ligand binding, in practice only the parameters that can be easily obtained and with high 
sensitivity are of interest, e.g. the changes in chemical shifts, relaxation times, diffusion 
constants, NOEs, or saturation exchange [8]. 
In protein-observed methods, normally the parameter of interest is chemical shift changes 
of the target protein upon ligand binding. The 3D structure of the complex can be identified by 
heteronuclear experiments of isotopically labelled protein. However, this approach is size limited, 
requires highly stable and soluble protein, and is time consuming [7]. 
 
2.4.1. Ligand-Observed Methods 
Because the protein NMR signals are not observed, the ligand-observed methods are not 
limited by the size of the protein. Large proteins (>50kD) can be studied via these techniques. 
These techniques require less protein (micromolar range) without needing isotope labeling. 
Ligand-observed methods can probe weak interactions and are used in obtaining information 
about affinities, specificity and 3D structures of protein-ligand complexes. One type of ligand 




NOE is an effective tool in determining the 3D structure of molecules in solution and in 
the structural analysis of proteins. Upon binding of ligand to protein, NOEs drastically change 
and transferred NOEs are observed. These changes are used to detect and characterize the 
binding. The observation of trNOEs is based on different tumbling times τc of molecules in the 
free and bound states. Molecules with low or medium MW (<1000-2000) have short correlation 
time τc, and depending on their MW and shape and the field strength, they have positive/zero/very 
small negative NOEs. Large molecules however have strong negative NOEs. When a ligand is 
bound to a large receptor it adopts the receptor NOE behavior and shows strong negative NOEs, 
called trNOEs. TrNOEs reflect the bound conformation of the ligand thus the sign and size of it 
characterizes the binding. Another discriminating factor between trNOEs and ligand NOEs is the 
build-up rate, i.e. the time required to achieve maximum intensity. For trNOEs, this value is in the 
range of 50 to 100 ms however for free molecules it is four to ten times as long. 
Intermolecular trNOE allow the determination of bound-ligand conformations thus intermolecular 
trNOEs can be used to determine the orientation of bound ligands in binding pocket of the 
receptor. 
Some experimental schemes that rely on the trNOEs include: Saturation Transfer Difference 
(STD) NMR Spectroscopy Experiments, Water-LOGSY, Cross Saturation, Transient Transferred 
NOE. 
Saturation Transfer Difference (STD) NMR Spectroscopy Experiments: If a ligand has two 
different signals because of a slow exchange between the bound and free states, by irradiating one 
of the ligand states, for example the free ligand signals, the signals of the other ligand state, here 
the bound ligand may be identified as a result of a transfer of saturation. In a method developed 
based on the transfer of saturation, saturation is transferred from the protein to the bound ligand. 




resonance signals with narrow line width. Then the off resonance spectrum is collected and 
finally subtracting the spectrum in which the protein is saturated (on-resonance spectrum) from 
the one without protein saturation (off-resonance spectrum) gives only the signals that are from 
the bound ligands and all molecules without binding activity are cancelled out [8, 9].  
The STD technique can be combined with any NMR pulse sequence giving powerful 
NMR experiments such as STD TOCSY, STD HSQC, etc. Another significant advantage of STD 
NMR spectroscopy is that it makes it possible to investigate the binding to membrane-bound 
proteins. 
STD can determine binding kinetics and binding constants of ligand-protein in both cases of one 
primary ligand and one primary ligand plus a secondary ligand which can have three schemes: 
independent binding sites for the primary and secondary ligands, allosteric inhibition and 
allosteric enhancement of the secondary ligand. 
 
Water-LOGSY (water-ligand observation with gradient spectroscopy): A variation of STD 
NMR spectroscopy uses the bulk water to detect the protein-ligand interactions. In Water-
LOGSY the 1H resonance of bulk water are excited and magnetization transfers from the bound 
water to the bound ligand.  
Intermolecular water-ligand interactions create a negative NOE peak. Just like STD NMR, on-
resonance and off-resonance spectra are obtained. One approach is using steady state NOE 
experiments in which on-resonance saturation is applied at the water chemical shift and the off-
resonance is applied outside of any ligand /protein resonances. Then the two spectra are 




Cross Saturation/Transferred-Cross Saturation: Transferred cross-saturation is an extension 
of cross-saturation and is used in finding the location of the interface between protein and ligand 
in large complexes (>150 kD) with low binding affinity. In cross saturation one protein is 
specifically isotope labelled. Utilizing the steady state NOE-difference experiment mapping the 
interaction sites in the complex is done. In this method if the two components are bound to each 
other, after irradiating the complex, only the labelled protein is affected. Saturated 1H resonance 
signals of unlabelled components leads to observation of magnetization of NH protons of the 
second deuterated and 15N-labelled protein. Saturation is further transferred on to the binding area 
of the labelled protein via cross-saturation. 1H- 15N HSQC spectra are recorded before and after 
irradiation. From these spectra, the intensity of the residues of the labelled protein located at the 
binding interface reduces [10]. 
Transient Transferred NOE: In transient NOE experiments high frequency pulses are used to 
generate a nonequilibrium state which will go back to equilibrium by relaxation in a mixing time 
period during which NOEs are generated. During the mixing time NOEs/trNOEs build up to a 
maximum value and then because of T1 relaxation, decrease to zero. Small molecules show 
positive NOEs and large molecules show negative NOEs which build up during mixing time. 
Two facts than can discriminate between ligands with binding activity from those without, is the 
difference in the sign of the trNOEs and NOEs and the difference times of reaching the maximum 
enhancement.  
 
2.4.2. Protein-Observed Methods 
Binding of a ligand to a protein changes the chemical shifts of the both molecules. Proton 
resonance signals can be affected by the local electron density, spatial proximity of groups with 




ligand and solvent, etc. The largest affected protein nuclei are the ones located in the binding 
pocket. One of the most common approached to study the protein-ligand interaction is the 
chemical shift mapping (CSM)/chemical shift perturbation (CSP)/complexation induced changes 
in chemical shifts (CIS). In chemical shift titration method, normally an unlabeled ligand is 
titrated into an isotope labeled (15N and/or 13C) protein and a 1D or 2D NMR spectrum is 
obtained after each titration to map a ligand binding site on a target and estimate KD. In theory a 
2D homonuclear NMR experiment, such as TOCSY, can provide a complete 1H NMR chemical 
shift map for the bound and free states and then the two can be compared. However in practice, 
for protein protons, signal overlap and difficulty in identifying the amino acids involved in the 
interaction results in ambiguous assignments. Thus, heteronuclear correlation NMR spectroscopy 
experiments are used. For ligand protons however signals are less overlapping and spectra is less 
complex thus the changes of ligand proton resonance signals can be used to study the binding. 
One of common approaches is determining the dissociation constant from titration experiments 
[8].  
One of the most common experiments used for the chemical shift mapping is 15N HSQC. 
For this purpose, proteins need to be uniformly labelled by 15N. Shifting of the resonance position 
of cross peaks in the spectra of the free protein as the reference versus the ligand bound protein 
samples, is indicative of binding. HSQCs are recorded during the titration and displaced peaks in 
the overlaid spectra shows the binding. Being involved in the binding is not the only cause of 
peak shifts. Conformational changes also can lead to peak shifts. Although there is  no direct way 
to distinguish the two sources, peak shifts that are due to a conformational change are usually 
observed in a region of protein which is buried inside or away from the interaction site [10]. 
Chemical shift titration can be used to find the dissociation constant of the weakly bound 
ligands and provides information about the binding strength. It is also used to find the binding site 




if the ligand binds to multiple binding sites with different affinities. In this case, peaks in 15N 
HSQC  spectrum shift linearly until the primary (stronger) binding site is saturated by the ligand 
and then changes the direction during the binding of the ligand to the secondary (weaker) binding 
site, producing a nonlinear pattern [10]. 
Chemical shift mapping is limited by the size of the protein since for larger proteins, 
slower molecular tumbling will cause faster transverse relaxation and the linewidth will increase. 
Thus 15N HSQC does not have good qualities for proteins beyond 40-50 kDa [10]. However, 
several techniques have been developed to push the size limit of protein, such as transverse 
relaxation optimized spectroscopy (TROSY), deuteration, stereoarray isotope labeling (SAIL), 
direct 13C detection or methyl-TROSY.  
Another improvement to protein-observed approach is adding an inert, freely soluble 
paramagnetic agent to the protein solution so increase the relaxation (both T1 and T2) of protein. 
This method is known as solvent paramagnetic relaxation enhancements (sPREs). A bound 
ligand protects the binding site from sPREs and is detected by reduced sPREs thus changes in 
linewidth. 
 
2.5. Limitations of NMR Spectroscopy 
Dipolar coupling which is due to the interaction between magnetic dipole moments of 
two close nuclear spins, has different manifestation in solid versus solutions. In solids very strong 
dipolar coupling of spins results in multiple levels of resonance splitting hence why spectra of 
solids has low resolution. In solution however due to fast tumbling of molecules dipolar 
couplings cancel out and on the timescale that NMR spectra is recorded it average to zero. This is 
why NMR peaks of proteins in solution state are sharp normally with perfect Lorentzian line-




coherence described by transverse relaxation rate R2. And this gives rise to the theoretical size 
limit of molecules that can be studies by solution NMR. Since coherence relaxes faster for large, 
slow tumbling molecules. One way to overcome this is protein deuteration, which due to its 
smaller dipole moment compared to proton, can greatly slow down the transverse relaxation. 
Moreover relaxation-optimized NMR experiments such as 1H-15N TROSY HSQC and methyl 1H-
13C TROSY HMQC has been developed to push the size limit.  
Another limitation of NMR spectroscopy is overlapping peaks in the NMR spectra of 
large proteins by which results in ambiguous assignments. In order to address this limitation, 







MOLECULAR MODELING STUDIES OF PROTEIN-LIGAND COMPLEXES 
 
3.1. Introduction 
Molecular modeling is a powerful tool in drug discovery and development. Incorporating 
experimental feedback in molecular modeling results is necessary to validate the computationally 
obtained results and to get the optimum results. Experimental methods for determining the 
complex structures are difficult and expensive thus using computational methods is a helpful tool 
in predicting complex structures. We have incorporated molecular docking via Autodock as well 
as molecular dynamic via GROMACS to investigate the ligand-protein interactions. 
Molecular docking is a computational tool to predict and rank the structure of the 
complexes formed between two or more molecules with known 3D structure. Binding modes and 
binding affinities of a complex can be predicted by molecular docking. Molecular dockings can 
be applied in molecular recognition studies including enzyme-substrate, drug-nuclei acid, protein-
nucleic acid, protein-protein, and protein-drug which is of great importance in structure-based 
drug design and is the focus of this study. 
42 years ago the first molecular dynamics simulation of a macromolecule (pancreatic 




greatly and now there are thousands of publications on molecular dynamics. Molecular dynamic 
give details of individual particles motions over time and can answer questions regarding the 
system that are otherwise hard to address via experiments. Comparing the simulation and 
experimental data can then be used to test the accuracy of the results and provide a gauge for 
improving the method. Improvements in the methodology and computer speed has extended the 
application of molecular dynamics to larger systems, greater conformational changes, and longer 
time scales. This can make it possible to get information beyond the access of experiments.  
In this chapter we review molecular dynamic tools, specifically GROMACS software and 
molecular docking tools, with the emphasize on AutoDock software.  
 
3.2. Molecular Docking Tools 
3.2.1. Introduction 
Study of ligand-receptor alignments and their binding sites traces back to 1982 when 
Kuntz et al. developed a geometric approach to study protein ligand interactions of heme-
myoglobin and thyroid hormone analogs with Prealbumin [11]. As mentioned, molecular 
docking, especially protein-ligand docking has an important role in drug discovery and 
development. In the initial applications of molecular docking, both the ligand and the receptor 
were assumed rigid bodies, thus only considering 6 degrees of translational and rotational 
freedom. New advancements lead to models in which ligand is assumed flexible and protein is 
assumed rigid. Some methods have been developed that consider both ligand and protein flexible. 
Flexibility assumption can improve affinity, binding site and binding orientation and gives more 
compatible results with experiment results, X-ray, etc. Lock and key theory has given its place to 
the models that implement the receptor/ligand flexibility assumptions. In current models instead 




several differently populated conformations in equilibrium. However, the highest unbound 
populated conformation is not usually the same as the highest populated in the complex. 
Docking protocols are a combination of sampling (also called search/pose) and scoring 
algorithms. In sampling, ligand-binding conformations in binding site of a protein are predicted. 
In scoring binding strength for these binding conformations are predicted and ranked with a 
physical or empirical energy function. The conformation with the lowest energy score will be 
predicted as the binding mode. The performance of most docking tools depends on the 
characteristics of the binding partners and there is no universal best algorithm/scoring function. 
The number of degrees of freedom (related to flexibility) in the conformational search is 
determinant of the searching efficacy. Molecular docking can be done fast and on large data and 
give reasonable solutions, which can be considered as a starting point for further accurate 
analysis. 
 
3.2.2. Sampling Algorithms 
Sampling algorithms can be divided into two main categories. Flexible ligand-search and 
Flexible protein-search. 
Flexible Ligand-Search: Flexible ligand-search algorithms include shape matching methods, 
systematic methods, random/stochastic, and simulation methods. 
Shape matching method is one of the simplest sampling/search algorithms. The initial 
placement of the ligand in the binding site of the protein is based on molecular surfaces being 
complement of each other. Six degrees of freedom (three translational and three rotational) is 
assumed for the ligand. DOCK, FRED, Ligand Fit, and FLOG are some the docking programs 
that implement this method. However since the ligand is normally conformationally fixed during 
this process, shape matching method takes an ensemble of pre-generated ligand conformations to 




Systematic docking algorithms, generates all possible ligand binding conformations by 
exploring all the degrees of freedom in ligand, can be further divided into 1) conformational/ 
exhausive search methods, 2) fragmentation search methods, and 3) database or conformation 
ensemble search methods. 
In conformational/exhausive search methods, all rotatable bonds rotate 360° with a fixed 
increment until all the possible combinations have been probed. One drawback of this method 
that makes its applications limited is “combinatorial explosion”, which is the dramatic increase of 
the number of generated structures with number of rotatable bonds. Thus, normally 
geometric/chemical constraints are applied and further optimizations takes place to make the 
docking practical. Glide and FRED use this method.  
In fragmentation method, ligand incrementally grows into the active site. This can be done via 
“the place-and-join” approach in which rigid ligand fragments are docked into the active site and 
covalently linked to make a ligand structure. It also can be done via dividing the ligand into a 
rigid core and flexible sites. Initially the core and subsequently the flexible sites are added. 
FlexX, DOCK, ADAM, Hammerhead, eHiTs, and LUDI use this. 
In database method, libraries of pre-generated conformations (conformation ensembles) are 
rigidly docked and then ligand binding modes from different docking runs are ranked according 
to their binding energies. FLOG, phDOCK, MDock, Q-Dock, MS-DOCK use this method. 
In random/stochastic algorithms random changes are applied to ligand(s). The changes 
will be accepted/rejected based on a predefined probability function. Four methods based on 
random algorithm are: Monte Carlo methods (MC), Genetic Algorithm methods (GA) or 
Evolutionary Algorithms (EAs), and Tabu. 
In Monte Carlo methods accepting/rejection criteria is based on Boltzmann probability function.  
 
P~exp [







E0 and E1 are energy scores of ligand before and after the random change, kB is the Boltzmann 
constant and T is the absolute temperature of the system. DockVision, ICM, MCDOCK, QXP, 
Prodock use this method. 
Genetic algorithms search for the most favorable binding mode is based on the idea of 
evolutionary process in biological systems. Starting from an initial population of conformations, 
by altering the variables that are indicative of translation, orientation, and conformation (genes) 
through applying genetic operators (mutations, crossovers, migrations) a final population of 
conformations that optimize a predefined fitness function will be obtained eventually. Autodock, 
GOLD, DIVALI, MolDock, PSI-DOCK, EADock and DARWIN. 
Tabu Search prevents the search from revisiting conformations that have been previously 
explored.  RMSD of new ligand binding conformations is compared with the previous 
conformations and if the RMSD between the new and previously recorded conformations is less 
than a cutoff, the new conformations will be rejected. PRO_LEADS, and PSI_Dock use this 
method. 
 
Simulation methods, which can be divided into molecular dynamics (MD), and pure 
energy minimization (EM) methods, find the solutions to Newton’s equations of motion.  
Energy minimization methods can be direct searches, gradient methods (e.g. steepest descend), 
conjugate-gradient methods, second derivative methods, and least squares methods. Autodock 
uses energy minimization methods.  
 
Flexible Receptor-Search: In order to have more accurate docking predictions, protein 
movements upon binding of the ligand should be accounted for. The basic principles here are 
same as flexible ligand search but with increased dimensions and search space. Assumption of 




has been considered, or an ensemble of protein conformations has been addressed instead of a 
single conformation. 
Methods that used to account for protein flexibility include: soft docking, side-chain 
flexibility, molecular relaxation, and protein ensemble docking [12].  
Softening the interatomic van der Waals interactions, soft docking, allows for some overlap 
between the ligand and the protein normally by using tolerant scoring function called soft core 
potentials. This method is computationally efficient, fast, easy to implement, and can detect 
subtle conformational changes on the receptor. However they only partially introduce flexibility. 
Side-chain flexibility keeps the backbones fixed and samples the side-chain conformations.  
Molecular relaxation initially docks the rigid-body of ligand into the binding site and then relaxes 
the surrounding protein backbone and side-chain residues. The formed complexes can then be 
minimized by Monte Carlo, Molecular Dynamics simulations, etc. Advantage of this method is 
allowing some backbone flexibility in addition to side-chain flexibility. However, in comparison 
to side-chain flexibility method, it is time consuming and more sensitive to the scoring functions 
and inaccuracies in the scoring function can cause artifacts. 
Protein ensemble docking is the mostly used method and it includes using an ensemble of protein 
structures to represent various possible conformations. The energy grids from each 
experimentally determined protein structure is combined to create a weighted average energy 
grid. This method is implemented in AutoDock. However, the averaging nature of the method 
may rise some inaccuracy. 
Applying a combination of different methods gives promising results. 
 
3.2.3. Scoring Functions 
Scoring functions, ΔG (in kcal/mol) are used to evaluate and rank the ligand 




important aspect of a scoring function is speed and accuracy. They can be categorized as 1) Force 
field-based, 2) Empirical, 3) Knowledge-based, and 4) Consensus. 
 
In force field-based scoring functions, ligand binding energies are decomposed into sum 
of several terms that identify interaction energies between the binding partners and the internal 
energy of the ligand. These interaction energies can be van der Waals energies (with a Lennard-
Jones potential), electrostatic energies (with a Coulomb potential), bond stretching/ bending/ 
torsional energies, etc. and apply a set of derived force-field parameters e.g. AMBER or 
CHARMM. 
Some force field scoring functions include Autodock scoring functions (which are based on 
Amber force field), G- and D- Scores and GoldScore.  
One of the major considerations in force field scoring is including the solvent effect. This can be 
achieved by using a distance-dependent dielectric constant, ɛ(rij). Some simplifications should be 
assumed to make scoring functions computationally less expensive. In a less computationally 
expensive approach, water can be treated as a continuum dielectric medium via implicit solvent 
models such as the Poisson-Boltzmann/Surface Area (PB/SA) or the Generalized-Born/Surface 
Area (GB/SA) models. 
 
In Empirical Scoring Functions such as Bohm’s, F-Score, and Chem-Score, binding 
energy score of a complex is approximated by a sum of uncorrelated empirical energy terms to 
reproduce experimentally determined data. E.g. VDW energy, hydrogen bonding, electrostatic 
interactions, entropy term, desolvation term, hydrophobic interactions, etc. [12]. 
 ΔG = W . ∆G  (3.2) 
Empirical scoring functions are much more computationally efficient compared to force field 




binding affinities of training set, the general applicability of an empirical scoring function 
depends of the choice of training set, i.e. the number of complexes in the training set. GlideScore, 
LigScore, F-Score, X-Score, SCORE, LUDI, ChemScore are some examples of empirical scoring 
functions. 
 
Knowledge-based scoring functions try to reproduce experimentally determined 
structures by taking the potential parameters directly from experimentally determined structural 
information. Compared to the last two scoring functions, the knowledge-based scoring functions 
are extracted from a large number of structures thus are relatively robust and general and have a 
good balance between accuracy and speed. Some challenges of knowledge-based scoring 
functions include extension of the pairwise interactions to many-body interactions (seen in 
hydrogen binding and directional interactions), accurate calculations of entropy, etc. Some 
examples are SMoG score, BLEEP, MScore, KScore, and DRUGScore. 
 
Consensus scoring combines different scores from several scoring function to 
compensate for errors from individual scoring functions and get a more accurate solution. The 
main issue is choosing the combination rule such that the true binders can be discriminated from 
others. X-CScore and MultiScore are two example. 
 
3.2.4. Challenges and Limitations of Molecular Docking 
Some main challenges for protein-ligand docking include the treatment of protein 
flexibility, solvation effects and structural water molecules, and entropy of binding.  
Flexibility of protein side-chain and backbone can affect characteristics of the binding 
site and binding conformation. Currently most docking methods account for ligand flexibility. 




difficult task to account for protein flexibility. As mentioned earlier, several techniques to 
account for flexibility of receptors include soft docking, side-chain flexibility, molecular 
relaxation, and protein ensemble docking. 
Solvation effect can affect the binding ability of a ligand. Solvation effect treatments 
have been included in many scoring functions. E.g. force field-based scoring methods employ a 
distant dependent dielectric constant, or empirical based scoring methods include desolvation 
energy term.  
Regarding the treatment of water molecules, an implicit representation of the solvent is 
not enough and an explicit atomic level description of water is needed. This can be done in 
several ways. Typical molecular mechanical force field include water models such as 3-point 
water models (e.g. TIP3P, SPC, SPC/E), or even more complicated models such as TIP4P and 
TIP5P. In case of strongly-bound or conserved structural molecules (observed in a variety of X-
ray structures), water molecule can be treated as an integral part of the protein/ligand for docking 
purposes. 
Entropic effects have an important effect to binding energy. Due to complexity of 
calculations, the entropy contribution is mostly neglected. Entropy contribution can be due to the 
reduction of the degrees of freedom upon binding, changes in normal modes of the binding 
partners upon binding, protonation and deprotonation events and arrangement of water molecules 
upon binding. Several attempts has been done to account for entropy in various ways such as 
clustering or including entropy in scoring function [13]. 
Most docking programs have average accuracies of about 1.5-2 Angstrom with 70-80% 
success rates [14]. The major limiting factor is in the scoring functions. Shortcoming of score 
functions in employing accuracy and speed is the biggest drawback. Simplifications used in 
scoring functions to lower the computational expenses, result in the loss of accuracy. For example 
not accounting for entropy and electrostatic interactions. Some other sources of complexity 




3.2.5. Comparison of Available Docking Softwares  
Over the last two decades more than 60 academic/commercial docking tools has become 
available such as AutoDock, AutoDock Vina, FlexX, Ligand Fix, Glide, FRED, DOCK, GOLD, 
and Surflex. Performance docking tools generally varies for different targets. In addition, the 
properties, which examine the quality of docking tools, may differ. Such as the prediction of 
binding free energy, the accuracy of virtual screening, and pose qualities. The assumption of 
approximation levels of different docking tools varies too. Thus, it is very difficult to make 
generally applicable conclusions. The power of a docking tool lies in its ability to reproduce 
experimental (X-ray, NMR) poses and in the liability of their scoring functions in predicting the 
free energy. Many studies have compared different programs based on different gauges e.g. 
accuracy in reproducing the X-ray conformations, capacity to predict binding free energies from 
the best scored conformation, etc. AutoDock, GOLD and FlexX are the most popular docking 
programs. 
In this study we have used AutoDock [15] and a newly designed version of AutoDock, 
AutoDock Vina [16]. AutoDock is a commonly used docking program developed by Morris & 
co-workers at the Scripps Research Institute [17, 18]. AutoDock 4.0 accounts for side chain 
flexibility on selected residues. Similar to GOLD, AutoDock creates ligand poses by using 
genetic algorithm. Autodock search algorithms include Monte Carlo Simulated Annealing 
algorithm, Genetic Algorithm, hybrid local search GA known as Lamarkian Genetic Algorithm 
(LGA).  
In AutoDock, a force field based on the AMBER force field is implemented with a 
Lennard-Jones dispersion, a hydrogen bonding, coulomb electrostatic potential, an entropic, an 
intermolecular pairwise desolvation terms. Scaling factors for force field terms are empirically 
calibrated from a set of 30 known complexes. Docking results from AutoDock can be done with 




In the last decade, AutoDock was the most cited protein-ligand docking program with 
around 500 citations per year (Figure 3.1). AutoDock Vina predicted top ranking poses with best 
scores and predict poses with RMSD averaging from 1.5 to 2 Angstrom from experimental poses 
[19]. 
AutoDock uses an empirical scoring function and the optimizer is GA-based. But 
AutoDock Vina uses a knowledge-based scoring function with a Monte Carlo sampling technique 
and Broyden-Fletcher-Goldfarb-Shanno (BFGS) method is used for local optimization. As a 
result of these modifications, both prediction accuracy and docking time is improved in 
AutoDock Vina [19]. AutoDock Vina was developed by Trott & Olson at the Scripps Research 
Institute, La Jolla, California [16]. It predicts more accurate binding modes and is also up to two 
orders of magnitude faster than AutoDock. Using new search and scoring algorithms, high 
computational efficiency and ability to use multiple CPUs, makes it a good candidate and a 
competitive alternative for virtual screening. 
 






3.3. Molecular Dynamic Simulations using GROMACS 
3.3.1. Introduction 
The software suite GROMACS (Groningen Machine for Chemical Simulation) was 
developed at the University of Groningen, in the early 1990s. GROMACS is a free, very fast, and 
reliable software for molecular dynamic simulations and energy minimization. GROMACS is 
written in C. It is compatible with all operating systems and makes parallel computing possible. 
The goal of molecular modeling is to understand and predict macroscopic physical properties 
based on detailed knowledge on an atomic scale. Macroscopic properties can be static 
(equilibrium) such as binding constants, or dynamic (non-equilibrium) properties, such as 
reaction kinetics. GROMACS is capable of investigating non-equilibrium dynamics. Macroscopic 
properties are ensemble averages over a representative statistical ensemble of system. Because 
single structure is not sufficient to compute thermodynamic equilibrium properties such as 
binding constants. Moreover averaging over the details that are not relevant for the macroscopic 
properties of interest simplifies the problem in hand. Although time-dependent Schrodinger 
equation describes the properties of the molecular system with high degree of accuracy, in 
practice any system more complex than the equilibrium state of a few atoms cannot be handled 
with such high accuracy and approximations are necessary. Two methods that are used to 
generate a representative equilibrium ensemble. Monte Carlo simulations and Molecular 
Dynamics simulations. MC simulations do not require the computation of forces thus are simpler 
than MD simulations. However, they do not yield significantly better statistics than MD. In cases 
where the forces are very large such as when the starting configuration is very far from 





3.3.2. Molecular Dynamics Simulations 
A system in GROMACS is defined by its size, shape, number, and type of molecules, as 
well as coordinates and velocities of all atoms it contains. Systems are simulated as triclinic boxes 
with periodic boundary conditions, encompassing all possible constructs.  
GROMACS supports GROMOS, Encad, OPLS-AA, Amber, CHARMM force fields. The 
forces are computed based on bonded and non-bonded interactions and special interactions.  
The bonded interactions include harmonic, cubic, Morse, periodic, Lennard-Jones potentials, etc. 
Bonded interactions are defined by one or more atoms, an enumerated index that defines the 
interaction and a set of parameters such as bonds, angles, and torsion, position and distance 
restraints, etc. Instead of applying interaction functions, SHAKE, LINCS, or SETTLE (for water) 
algorithms can be applied to constrain bond lengths and angles to given values. 
Non-bonded interactions consist of a Lennard-Jones 6-12 potential or a Buckingham exponential 
term potential and a Coulomb term. One can use arbitrary tabulated functions for non-bonded 
interactions. Long-range interactions can be addressed by employing cutoffs.  
Special interactions can be defined to impose position, angle, and distance restraints on the 
system to add a penalty to the potential energy while some threshold is exceeded.  
The influence of electrons in a molecular mechanics (MM) force field is expressed by 
empirical parameters from experimental data or from the results of high level quantum 
calculations. The accuracy of MM approximation is sufficient for the ground state processes of a 
covalent structure where the overall connectivity of atoms does not change. However, in case of 
chemical reactions or processes that involve multiple electronic states where the connectivity of 
atoms changes, electrons cannot be ignored and a quantum mechanical description is needed. One 
approach is to use a combination of quantum mechanics and molecular mechanics, QM/MM in 
which the reacting parts of the system are treated quantum mechanically and the rest of the 




In studying the conformational dynamics of the macromolecules, for example in protein 
folding, it is important to get the longest possible time step without losing much accuracy. 
One can find free energy of the system using GROMACS. Two types of free energy can 
be obtained from the simulations. One is a difference in Gibbs free energy between two 
thermodynamic states of a system, e.g. bound and free states of protein-ligand complex. We can 
get the binding constant of the ligand this way. The other type is a potential of mean force and 
includes a free energy profile as a function of reaction coordinate(s), which can be served as a 
restraint or constraint.  
MD simulations finds the solutions of Newton’s equations of motion for a system 














The coordinates of the system is recorded to an output file at regular intervals while average 
temperature and pressure is kept constant at specific defined values. The recorded coordinates 
form the trajectory of the system. After enough time the system reaches an equilibrium state. 
Many macroscopic properties can be found by averaging over an equilibrium trajectory. Basic 










Table 3.1 Basic units used in GROMACS 
Mass u (unified atomic mass unit, ~1.66 e-27 kg) 
Length nm 
Time ps 
Charge e (elementary charge, ~1.60 e-19 C) 
Temperature  K 
 
 





GROMACS interfaces with quantum mechanical packages e.g. Gaussian and Mopac thus 
can perform mixed MM/QM simulations. It implements microcanonical Hamiltonian mechanics, 
stochastic dynamics (SD) including Langevin and Brownian dynamics and energy minimization. 
GROMACS allows various coupling methods to temperature and pressure baths, anisotropic 
pressures, triclinic box changes to address pressure tensor fluctuations. It is also possible to 
organize atoms in special groups and study their selective participation in dynamics or for energy 
calculations. User defined atom selections can be stored in index files by using make_ndx 
interactive program. This provides a very flexible way of performing operations on a subset of a 
system. Some example of such analysis which are used in investigating protein-ligand 
interactions include [20]:  
 Protein secondary structure analysis 
 Computing chemical shifts 
 Calculating Relaxation times for molecular motion 
 Ramachandran plots 
 Dihedral angle calculations 
 Analysis of energy components between default/user defined groups of atoms 
 Root mean square deviations (RMSD) of a trajectory against itself, against another 
trajectory, or between a reference structure and a trajectory.  
 RMSD of pairs of distances 
 Analysis of hydrogen bond and hydrogen bond lifetime  
 Analysis of formation/breaking salt bridges  
 Analysis if bind length distributions 






Periodic boundary conditions: Periodic boundary conditions are applied to minimize 
edge effects in a finite system. Space-filling boxes/unit cells of atoms is surrounded by copies of 
itself thus there are no boundaries. Periodic boundary conditions is combined with the minimum 
image convention in GROMACS. According to minimum image convention, only the nearest 
image of each particle is considered for short-range non-bonded interaction terms. The cut-off 
radius that is used to truncate non-bonded interactions cannot be greater than half of the shortest 
box vector. Because otherwise more than one image will be in the cut-off distance. 
The Group Concept: In GROMACS certain actions are performed on user-defined 
groups of atoms. Each atom can only belong to 6 different groups. Possible groups can be 
temperature-coupling group, freeze group, accelerate group, energy monitor group, center of 
mass group, and compressed position output group.  
 
3.3.4. Finding the Binding Free Energy 
Molecular Mechanics can be combined with Poisson Boltzmann Surface Area 
(MM/PBSA) to estimate free energy of bonding of ligand to macromolecule. In this method, 
binding free energy of a protein-ligand complex is calculated as: 
 Gbind = GPL – (GP + GL) (3.5) 
 
G is the free energy. GPL, GP and GL are average free energies of the complex, the isolated 
protein, and isolated ligand respectively. The free energy G for each individual entity is given by: 
 G = EMM  – TS + Gsolvation= 






where S is solute entropy and Enonbond =Evdw + Eelec modelled with Coulomb and Lennard-Jones 
potential functions. Free energy of solvation, Gsolvation, is the energy required to transfer a solute 
from vacuum into the solvent. Therefore,  
 Gbind = Ebond + Evdw + Eelec + Gpol + Gnonpol – TS (3.7) 
 
The first three terms are energy terms from bonded (including bond, angle, and dihedral), van der 
Waals, and electrostatic interactions. Gpol and Gnonpol are polar and non–polar contributions to 
the change in solvation free energy, T is the absolute temperature and S is the change in solute 
entropy [21-23]. The polar solvation energy addresses the electrostatic interaction between the 
solute and the solvent. Three extra energy terms of cavitation, dispersion, and repulsion are 
needed to obtain solvation energies. These energy terms represent the cost of making a cavity in 
the solvent, the attractive and repulsive parts of van der Waals interactions between the solvent 
and salute. Gnonpol=Gcavity +Gvdw. Gcavity is the work done by the solute to create a cavity in the 
solvent. This term depends on the geometry of the solute. Gvdw is the attractive energy between 
the solvent and solute. 
In order to calculate these MMPBSA energy terms we used GORMACS tool, g_mmpbsa [24].  
 
3.3.5. Limitations of MD Simulation 
Due to limitations of MD simulations, it is necessary to check the known experimental 
properties to test the accuracy of the simulations. Some of these limitations are as follows.  
The MD simulations are classical: The fact that MD simulations used classical mechanics to 
solve Newton’s equation of motion, does not cause a problem for most atoms at normal 
temperatures, however, there are exceptions. E.g. Hydrogen atoms and tunneling of proton 




the high frequency vibrations of covalent bonds that are quantum oscillators rather than classical 
harmonic oscillators. 
Force fields are approximate: The GROMACS force fields which provide the forces, is pair-
additive, they cannot incorporate polarizabilities and do not contain fine-tuning of bonded 
interactions. 
Electrons are in the ground state: The electronic motions of the atoms are not considered in 
MD simulations, rather the force field is a function of the position of the atoms only and atoms 
remain in their ground state upon position changes (the Born-Oppenheimer approximation). 
Long-range interactions are cut off: A cut-off radius is considered for the Lennard-Jones and 
Coulomb interactions. According to the minimum image convention of GROMACS, only one 
image of each particle in the periodic boundary condition is considered for a pair interaction. 
Thus, the cut off radius has to be less than half the box size.  
Boundary conditions are unnatural: Periodic boundary conditions are used to avoid real phase 
boundaries. The GROMACS system size is small and in small systems the GROMACS boundary 







SHETA2 AND MORTALIN INTERACTION 
 
4.1. Introduction 
Retinoids are natural or synthetic vitamin A derivatives with clinically proven anti-cancer 
activities. However, the toxicity of retinoids has limited their application in vivo. Attempts to 
improve anticancer activities of retinoids while reducing their toxicity have resulted into 
variations of retinoids. Heteroatom substitution on the ring in retinoids structure leads to 
generation of a new class called heteroarotinoids with dramatically lower toxicity compared to 
retinoids. Further modification led to generation of flexible heteroarotinoids (Flex-Het). Flex-
Hets contain a flexible linker between the heteroatom ring and aryl ring. A variety of Flex-Hets 
has been tested and among all, N-(3,4-dihydro-2,2,4,4,-tetramethyl-2H-1-benzothiopyran-6-yl)-
N’(4-nitrophenyl)thiourea, also known as SHetA2, is the most promising compound with the 
highest anti-cancer activity. SHetA2 is effective against all of over 60 cancer cell lines in the US 
National Cancer Institute [25] and is a candidate for clinical trials for the treatment of ovarian 
cancer. It induces both intrinsic (mitochondrial mediated) and extrinsic (death receptor mediated) 
apoptosis pathways in cancer cells [26] and has low toxicity and differential activity against 
malignant versus normal cells [27, 28]. SHetA2 has been shown to interfere and interact with the 
activity of the heat shock protein HSPA9 (mortalin) [26]. Mortalin on the other hand interacts 




pathway for the compounds to inhibit the growth of cancer cells in vitro is by displacing p53 from 
mortalin. Binding of SHetA2 to mortalin interrupts p53-mortalin complex, allowing p53 migrates 
to the nucleus where it initiates apoptosis. However, interactions of mortalin with other client 
proteins, such as Bcl-2 and p66shc, may also impact cell apoptosis. Here we review the chemistry 
evolution, anti-cancer activity, and biological mechanism of heteroarotinoids, specifically 
SHetA2. Mortalin-SHetA2 interactions and its role in induction of apoptotic is reviewed next. 
Other mortalin-p53 inhibitors are reviewed briefly.  
 
4.2. Review of Flex-Hets 
4.2.1. Flex-Hets Chemistry Evolution 
SHetA2 belongs to a relatively new chemical class, flexible heteroarotinoids (Flex-Hets), 
which have been evolved progressively from retinoids, to arotinoids, and to heteroarotinoids.  
Retinoids are natural or synthetic vitamin A analogues/derivatives with at least one 
aromatic ring. The study on retinoids originates back from the exploration of Vitamin A 
metabolism [28]. Retinoids’ mechanism of action is through their interaction with two types of 
nuclear receptors, the retinoic acid receptors (RARs) and the retinoid X receptors (RXRs). As the 
regulators of these retinoid receptors, retinoids have chemotherapeutic and chemopreventive 
properties in a variety of cancers in animal models and human cell lines. Retinoids regulate gene 
expression, control developmental, metabolic, and differentiation mechanisms, and induce growth 
inhibition and apoptosis in cancer cells in vivo and in vitro [29]. 
A retinoid molecule consists of a cyclic group, a polyene side chain, and a polar end 
group (Figure 4.1). Naturally occurring retinoids include Retinol (aka Vitamin A1), Retinal 




acid (13-cis-RA, 2). They are shown to be potential chemotherapeutic and 
chemopreventive agents [30-33].  
 
 
Figure 4.1 Natural retinoids.  
(A) retinol/vitamin A, (B) retinal/retinaldehyde, (C)  isotretinoin/13-cis-RA, (D) tretinoin/all-
trans-retinoic acid (t-RA), and (E) alitretinoin/9-cis-RA 
 
However, the clinical applications of retinoids are limited due to innate and acquired 
resistance in some malignant cells and significant side effects associated with their activation of 
nuclear receptors, such as teratogenicity and toxicity to skin, mucous membranes, gastrointestinal 




retinoids toxicity, to increase the potency (half-maximal inhibitory concentration IC50), and to 
overcome resistance have led to design and synthesis of novel retinoids [36], such as 6-[3-(1-
adamantyl)-4-hydroxyphenyl]-2-naphtalene carboxylic acid (AHPN/CD437), N-(4-
hydroxyphenyl)retinamide (Fenretinide or 4-HPR), bexarotene (LGD1069), arotenoids, 
heteroarotenoids, and Flex-Hets. CD437 is a RARγ activator that showed significant apoptosis-
inducing activity in a variety of cancer cells in vivo and in vitro [37, 38]. The synthetic amide of 
retinoic acid, Fenretinide, is a widely studied chemopreventive agent that inhibits the growth of 
several human cancer cell lines. Fenretinide induces apoptosis through both retinoid acid 
receptor-dependent and receptor-independent mechanisms [39]. It has good efficacy (maximal 
inhibition of cancer cell growth) compared with other retinoids, with no acute or severe toxicity 
and causes no liver function abnormalities. However, Fenretinide showed a few side effects in 
clinical trials including impaired dark adaptation (night blindness) resulted mainly from reduction 
of circulating retinol [40, 41]. LGD1069 is a synthetic derivative of 9-cis retinoic acid that 
showed more potency and less toxicity than its parent compound. However, the compound 





Figure 4.2 Synthetic arotinoid (A) TTNPB and (B) Heteroarotinoids 
To improve retinoids, arotinoids (Figure 4.2A) were synthesized by adding an aromatic 
ring to constrain the retinoic acid double bonds of retinoids. The first arotinoid 4-[(E)-2-(5, 6, 7, 
8-Tetrahydro-5, 5, 8, 8-tetramethyl-2-naphthalenyl)-1-propenyl]benzoic Acid known as TTNPB 
activates RARs instead of RXRs. Arotinoids have better anticancer activity than retinoids but 
intolerably higher toxicity [44, 45].  
Further attempts were made to develop mimics of trans-retinoic acid and arotinoids with 
similar clinical effects but less toxicity and side effects. To reduce toxicity, oxygen or sulfur 
replaced a carbon atom in the tetrahydronaphthalene ring of TTNPB. The resulting compounds 
were named heteroarotinoids (Hets) (Figure 4.2B) [46]. Heteroarotinoids have structural 
relationship to diarylureas. Diarylurea and its derivatives are important pharmacophores with 




The partially saturated aromatic ring can be five or six-membered, with at least one heteroatom 
(O, S, N, etc.). The heteroatom can block the benzylic oxidation of the parent arotinoids to toxic 
metabolites, reducing in vivo toxicity by up to 1,000-fold, comparable to the level of a natural 
retinoid, all-trans retinoid (t-RA) [46]. The linker between the heterocyclic ring and the aryl ring 
can be a two or more atoms moiety and it can be an amide, alkene ester, urea, thiourea, etc. 
Heteroarotinoids have been tested against various cancer cell lines such as kidney, lung, head and 
neck, and breast cancers and showed high activity and low toxicity [48-51]. Hets have similar 
anti-cancer activity as retinoids by activating RARs and inducing gene regulation [46, 52]. 
Arotinoids and t-RA only activate RAR receptors while 9-c-RA and some heteroarotinoids 
activate both RAR and RXR receptors [53, 54].  
The specificity for retinoid receptors can be changed by alterations in the structure of the 
compound. Benbrook and colleagues. synthesized several heteroarotinoids and studied the effect 
of structural characteristics like heteroatom, ring size, number of aryl groups, and terminal side 
chain on the retinoid receptor [55]. In general six-membered ring had greater efficacy and 
specificity for RAR than five-membered rings. Monoaryl compounds had lower RAR receptor 
specificity but greater efficacy. The effective concentration (EC50) values of sulfur containing 
heteroarotinoids for RAR were lower in diaryl, whereas the opposite relationship was observed 
in oxygen containing compounds.  
Dhar et al. synthesized three heteroarotinoids with a nitrogen heteroatom and a two atom 
C-O linker group [49] and studied their RAR and RXR activation, biological activity, and growth 
inhibition against cervix, vulvar, ovarian, and head/neck tumor cell lines. In comparison with the 
positive control, 4-HPR, the modified nitrogen heteroarotinoids had low apoptosis effect like t-
RA and were classified as nonapoptotic retinoids.  
Zacheis et al. evaluated growth inhibition activity of 14 heteroarotinoids against two 




suggested that heteroarotinoid induced growth inhibition through the regulation of gene 
expression via the nuclear retinoic acid receptors. For most tested heteroarotinods, the tumor size 
had statistically significant reduction while no significant toxicity was observed.  
Brown at al. ranked the antibacterial activity of 15 heteroarotinoids against 
Mycobacterium bovis according to their MIC values (defined as the lowest concentration of drug 
in μg/mL of drug that results in 99% reduction in the number of bacterial colonies compared to 
the control drug free plate) [56]. The result revealed the inhibitory ability of these first examples 
of heteroarotinoids against the growth of M. bovis. 
 
4.2.2. Flex-Hets 
Further exploration led to a more potent class of Hets called Flexible Heteroarotinoids 
(Flex-Hets) (Figure 4.3). Flex-Hets have a three-atom flexible linker of urea or thiourea linker 
group between the heterocyclic ring and the aryl ring. 
In vitro experiments on cancer cells have shown that Flex-Hets regulate growth, 
differentiation and apoptosis, similar to conventional Hets. However, unlike conventional 
conformationally restricted two-atom linker Hets, Flex-Hets induce apoptosis independent of 
retinoic acid receptors RAR/RXR, hence not causing toxicity like skin irritation, genotoxicity, 






Figure 4.3 Structure of thiourea/urea containing heteroarotinoids, Flex-Hets  
[58]. SHetA2 (X=H, Y=S, Z= NO2, Z’=H), SHetA3 (X=H, Y=S, Z= CO2Et, Z’=H), and SHetA4 
(X=H, Y=O, Z= CO2Et, Z’=H). 
 
Although Flex-Hets regulate growth and induce differential apoptosis in cancer cells, in 
normal cells they induce growth inhibition only [25]. Benbrook and colleagues [60] have studied 
the hypothesis that Flex-Hets induce differential apoptosis by directly targeting the mitochondria. 
Mitochondria is involved in cell growth and death. B-cell lymphoma 2 (Bcl2) family of proteins, 
which reside on the mitochondria outer membrane, are responsible for maintaining the integrity 
of mitochondria. This family consists of anti-apoptotic (Bcl-xl, Bcl-2, Bcl-w, Mcl-1, Bcl-b, A1) 
and pro-apoptotic (Bak, Bim, Bad, Bik, Bax, Bid, Bcl-xs, Noxa) protein members. The pro-
apoptotic members of this family destabilize mitochondria by forming pores in mitochondria and 
inducing apoptosis. While anti-apoptotic members interrupt pore formation in mitochondria. Thus 
in order to regulate cell apoptosis the balance between members of Bcl-2 family is important. 
Mitochondrial mutations and disturbance of the balance between pro-apoptotic and anti-apoptotic 
mitochondria proteins could lead to mitochondria destabilization. Having unstable mitochondria 
due to their higher metabolism and mitochondria mutations, cancer cells are more susceptible to 
Flex-Hets than normal cells. Flex-Hets affects expression of Bcl2 family of proteins. They 




cancer cell and increase their expression in normal cells in a time dependent manner. Meanwhile 
the pro-apoptotic expression levels are not changed as shown in ovarian, kidney, or lung cells 
lines [60-62]. The receptor-independent differential apoptosis induced by Flex-Hets occurs due to 
the loss of mitochondrial membrane integrity. In this process ROS (Reactive Oxygen Species) is 
generated, which consequently can alter membrane potential and release caspase activating 
factors such as cytochrome c [58, 60, 63].  
The major concerns regarding the toxicity of any mitochondria-targeting drug are effect 
on the mitochondria in normal cells and increased ROS levels. Increase of ROS levels to levels 
exceeding the capacity of detoxifying enzymes can lead to ROS-induced cellular damage and 
cause potentially carcinogenic change in cells. A good drug candidate should have least effect on 
normal cells, and maximum effect on cancer cell. As mentioned, normal cell lines show more 
resistance to Flex-Hets than cancer cell lines. 
 
4.2.3. Sulfur-Heteroatom Flex-Hets 
Studies have been done in search of the most promising Flex-Hets. Several Flex-Hets 
with urea and/or thiourea linking groups and an ester or nitro group or sulfonamide group at the 
para position of the single phenyl ring were synthesized and studied [58].  
Chun et al. performed a preclinical study in which the activity of six synthetic  
heterorenoids against eight HNSCC human cell lines were tested [63]. In this study, a sulfur 
containing heteroarotinoid with thiourea linker (SHetA2) was the most potent among the six Hets 
and natural RAs (all-trans- and 9-cis-RA). In vitro studies confirmed greater activity of 
compounds with a sulfur heteroatom as previously was shown in other studies [46, 50].  
Studies have shown reduced toxicity of some sulfur heteroarotinoids is associated with 
activation of nuclear RARs and RXRs [46, 57]. Classification of some apoptotic rotinoids based 




4.4A) show no activity towards nuclear retinoid receptors when used at doses up to 10 μM and 
they show much greater growth inhibitory effects towards cancer cells than normal or benign 
cells. SHet50(Figure 4.4B, with 2-atom amide linker) , however, is both RAR and RXR receptor 
pan-agonist.  This induced differentiation and apoptosis was observed in vitro in cancer cell lines 
[57, 58].  
 
Figure 4.4 (A) Receptor-independent heteroarotinoid, SHetA2, SHetA3, and SHetA4. (B) 
Receptor-active heteroarotinoid, SHetA50. 
Berlin et al. [58] synthesized sulfur-containing Flex-Hets with urea/thiourea linker and 
studied their growth inhibition effect against some ovarian cancer cell lines. They compared the 
efficacy and potency of these Flex-Hets with each other and with 4-HPR. Results showed that 
sulfur-containing heteroarotinoids have similar range of EC50 as 4-HPR and that Flex-Hets do not 




compared to normal cells, and enhanced the growth inhibitory ability of Flex-Hets against ovarian 
cancer cell lines compared to 4-HPR. 
Le et al. reported that NO2 group was also slightly more potent than CO2Et, urea linker 
analogs were slightly more potent than thiourea linker compounds (e.g. SHetC2 with SHetA2), 
and a flexible thiochroman ring unit instead of planar quinolone, increases inhibitory activity and 
apoptosis significantly [64]. Compounds having nitro substitute on the phenyl ring, like SHetC2 
and SHetA2, have greater growth inhibition than those having methyl or ethyl ester substitute like 
SHetA3, SHetA4, SHetD3, and SHetD4 (Figures 4.4 and 4.5) [62].  
 




Gnanasekaran et al. [65] synthesized a series of 11 compounds with a 4-atom acrylamide 
linker  (Figure 4.5B) and studied the biological activity against the A2780 ovarian cancer cell 
line. In general, electron-withdrawing groups on the linker, showed enhanced activity compared 
to electron donating groups. Among these new Flex-Hets, the most active candidate is still only at 
comparable level to SHetA2. 
Among all the sulfur-hetroatom Flex-Hets, SHetA2 has exhibited the highest efficacy and 
potency without toxicity in vivo [25, 66] and strong chemopreventive activity in murine tumor 
and in human cell culture. SHetC2 has almost equal efficacy and potencies as SHetA2 for 
inhibiting the growth of renal cancer cells and inducing apoptosis. Therefore it is a reasonable 
alternative for SHetA2 [64]. SHetA2 showed growth inhibitory activities against all 60 cell lines 
in NCI human tumor panel at micromolar concentrations [25]. Animal studies and preclinical 
studies did not show evidence of any general toxicity, bone, skin or liver toxicity, teratogenicity, 
carcinogenicity, mutagenicity, and skin irritancy for SHetA2 [25]. Genetic toxicology assay 
showed SHetA2 is not mutagenic or genotoxic [67, 68]. Growth inhibition and apoptosis effects 
of SHetA2 has been studied in NSCLC cells both in vitro and in vivo [69], in organotypic cultures 
of ovarian cancer cell lines [57, 64], cervical cancer cell lines[25], in head and neck cell 
carcinoma [59, 63], lung cancer [61, 70], kidney cancer [62], colon and small intestinal cancer in 





Figure 4.6 Structure of (A) SHetA2, (B) primary metabolite of SHetA2 
Structural similarity of SHetA2 and its metabolite (Figure 4.6) to diarylureas, helped 
preliminary assessments of their binding using molecular docking (using Glide docking program) 
[72]. Two well-known diarylureas, Sorafenib and Imatinib, were employed as the reference and 
their kinase interactions was studied by molecular docking to B-Raf and KIT and also 
experimentally confirmed. Sorafenib and SHetA2 had similar orientation in binding site of B-Raf. 
Moreover, thiourea in Sorafenib and urea in SHetA2 formed similar H-binding with Glu501 and 
Asp549 of B-Raf.  
Imatinib and the SHetA2 metabolite had the similar binding site in KIT 4 H-bonds with 
Asp810, and Glu640 and hydrophobic contact with hydrophobic binding pocket of KIT. The 
results suggest that SHetA2 and its metabolite have the potential to be inhibitor of B-Raf and 
KIT.  








4.2.4. Oxygen-Heteroatom Flex-Hets 
 
Figure 4.7 Oxygen analogs of SHetA2 
In a recent study [73] and as we mention in chapter 7, in order to enhance aqueous 
solubility, oxygen analogs of SHetA2, with both urea and thiourea linkers, in presence of 
germinal dimethyl/diethyl in ring A, and different substituents on ring B with H-bonding 
capability (NO2, CF3, CN, OCF3, CO2Et, SO2NH2 have been studied (Figure 4.7). Their potency, 
efficacy against human A2780 ovarian cancer cells in vitro, and binding free energy values in 
silico are compared. A positive correlation between potency-binding free energy and a negative 
correlation between efficacy-binding free energy and potency-efficacy is observed. Among the 
tested compounds, the group of compounds with NO2 substituent and urea linker, had efficacy 
values of 91-94% and IC50 values of 2.0-2.4 M which is significantly better than the 
corresponding values for SHetA2 being 84% and 3.2 M respectively. Compounds where docked 
into substrate binding domain of mortalin using Autodock 4.2 [74]. Docking results which was 
then confirmed by cellular dose-response data showed improved activity of 1) urea linker-
containing compounds over thiourea counterparts, 2) germinal diethyl-containing compounds at 
C2 position of ring A over compounds with germinal diethyl at C4 or compounds with germinal 
diethyl at both C4 and C2 position of ring A, and 3) NO2-containing compounds over CF3 or other 





4.3. Biological Activities of Flex-Hets 
As mentioned SHetA2 differentially induces apoptosis in cancer cells. Differential effect 
of SHetA2 has been observed in vivo, e.g. in ovarian cancer xenografts [25], in ovarian cancer 
cell lines versus normal HOSE cells [75], and in the Caki-1 kidney cancer cell lines versus 
normal kidney cells [62]. Resistance of mitochondria to SHetA2 in normal cells has been 
confirmed by lack of cardiac toxicity in treated wild type mice versus untreated mice at the 
highest dose used [71]. 
Study of the role of RNA and protein synthesis in SHetA2’s mechanism of action has 
showed that SHetA2 works independently from regulation of gene expression [60]. Similar to 
other Flex-Hets, SHetA2 induces differential cell apoptosis independent of the retinoic acid 
receptor-signaling pathway and by directly targeting mitochondria [63]. 
 
4.4. Apoptosis Pathways 
There are two major apoptosis pathways: extrinsic death receptor (DR)-induced pathway 
and intrinsic mitochondria-mediated pathway, which involve activation of caspase-8 and caspase-
9 respectively [76]. Intrinsic and extrinsic pathways converge through Bid protein [77]. SHetA2 
induces both intrinsic and extrinsic apoptosis [78].  
Lin et al. [61] studied the effect of SHetA2 on expression levels of some apoptosis 
regulator proteins. They found that in Human NSCLC cells, SHetA2 down-regulates both c-FLIP 
(a major inhibitor of extrinsic apoptosis) and Survivin (a major inhibitor of intrinsic apoptosis) in 
all 6 testes cell lines and that it reduces the levels of several other apoptosis regulator proteins like 
XIAP, Bcl-2, Bcl-xl in some tested cell lines. Overexpression of c-FLIP makes cells resistant to 
SHetA2-induced apoptosis alone or combined with TRAIL. Overexpression of Survivin does not 




Survivin and c-FLIP enhances SHetA2 and TRAIL-induced apoptosis with the later having more 
effect.  
Myers and colleagues [66] demonstrated anti-angiogenic activity of SHetA2 through 
microarray analysis of ovarian cancer organotypic cultures and showed that Flex-Hets regulate 
expression of angiogenic cytokines. Thus by blocking cytokine release from cancer cells, 
SHetA2, inhibits angiogenesis. In this study, 44 genes were significantly regulated by SHetA2. 
SHetA2 reduces the expression of Thymidine Phosphorylase (anti-angiogenic growth factor) in 
cancer cells but not normal cells. Angiogenic inhibition of SHetA2 in vivo has been confirmed in 
Caki-1 renal cancer xenografts.  
As mentioned above, SHetA2 can induce intrinsic apoptosis [63]. Alteration in the 
mitochondrial membrane potential, suppression of mitochondrial membrane permeability 
transition (MPT), and loss of mitochondria integrity enhances the release of caspase-activating 
factors like cytochrome c from mitochondria to the cytosol. The released cytochrome c interacts 
with cytosolic factors like Apaf-1 and dATP, thus activates caspase-9 and caspase3-like activity 
in a time dependent manner. SHetA2 treatment can cause mitochondria swelling and loss of 
mitochondria membrane potential, resulting in activation of intrinsic apoptotic pathways [79]. 
SHetA2 directly affects on mitochondria and reduces anti-apoptotic proteins, Bcl-2 and Bcl-xl in 
ovarian, kidney, lung cells lines, and in colon polyps [71] leading to apoptosis. In normal ovarian 
and endometrial cells, SHetA2 increases Bcl-x2 and Bcl-xl protein levels, blocking apoptosis in 
normal cells [60]. In vitro study showed that SHetA2 did not change Bax level in either normal or 
cancer cells [60]. Also SHetA2 binding to heat shock protein A (HSPA9, HSPA8, and HSPA5) 
[80] in both normal and cancer cells leads to cyclin D1 degradation thus G1 cell cycle arrest (with 
greater effect on cancer cells compared to normal cells) [62, 81, 82].  
SHetA2 reduces the expression of Bcl-2 in cancer cells thus promotes apoptosis [60, 62] 




SHetA2 can regulate the Bcl-2 protein family and affect the stability of mitochondria. (Activation 
of Bax is in favor of apoptosis and activation of Bcl-2 inhibits initiation of apoptosis). 
Interestingly, Liu and colleagues tested the hypothesis that SHetA2 induces 
mitochondrial effects through ROS generation and found that ROS generation is a consequence 
of Flex-Het action on mitochondria and not a cause of it [60, 62]. 
SHetA2 can activate DRLs (Death Receptor Ligands) and induce extrinsic caspase-8-
dependent apoptosis by differentially sensitizing cancer cells while not affecting normal cells. 
DRLs (such as Tumor necrosis factor  (TNF) and TNF-related apoptosis inducing ligand 
(TRAIL)) and death receptor activating antibodies have been used in cancer therapy. Compounds 
that can increase sensitivity of resistant cells to death receptor activating ligands without 
increasing toxicity are of great importance in cancer therapy. Clinical trials on TNF failed due 
to its resistance and toxicity [83, 84]. In attempt to reduce the toxicity of TNF, tumor-selective 
delivery of TNF via SHetA2 has been studied. SHetA2 represses nuclear factor κB (NF-B) 
activity [62, 82]. Some NF-B inhibitors sensitize other types of cancer to death receptor ligands 
[66, 85]. Similarly SHetA2 sensitizes ovarian cancer cells to TNF-induced apoptosis effects in a 
mechanism that involves repression of NF-B [86, 87]. SHetA2 may also sensitize cancer cells to 
other death receptor ligands [69] . 
             Lin and colleagues [70] showed for the first time that SHetA2 induced a caspase-8-
dependent apoptosis mechanism, in which SHetA2 induced CHOP expression and up-regulated 
death receptor 5 (DR5) in human lung cancer in cell cultures and in mice. DR5 induction is thus a 
key factor of SHetA2-iduced apoptosis or SHetA2-TRAIL-induced apoptosis.  
             Moxley et al. [86] studied the effect of chemotropic agents cisplatin, paclitaxel, and 
SHetA2 with TNF and TRAIL on ovarian cell lines A2780 and SKOV3 and normal human 
endometrial cells. The result revealed normal and cancer cells are resistant to the death receptor 




not eliminate this resistance. However, dose responsive apoptosis effect of SHetA2 was enhanced 
when combined with TNF and TRAIL. SHetA2 when combined with TNF and TRAIL 
sensitized cancer cells and induced an extrinsic casapase-8 and -3 apoptotic pathways. Moreover, 
SHetA2 did not affect the sensitivity of normal cells. Simultaneous treatment of SHetA2 and 
TNF not only induces caspase 8-dependent extrinsic apoptosis but also SHetA2 enhances 
caspase 9-dependent intrinsic apoptosis activity of SHETA2 as a single agent [78, 86].  
             SHetA2 induction of cell cycle arrest, can be effective in broad type of cancer cells, 
regardless of presence or absence of p53 in cells [82]. 
The National Cancer Institute’s Rapid Access to Intervention Development (RAID) 
program (Application 196, Compound NSC 721689) and Rapid Access to Preventive Intervention 
Development (RAPID) program completed preclinical testing on SHeA2. Not showing toxicity 
effects in preclinical trials, SHetA2 is now in Phase-0 clinical trial. 
 
4.5. Mortalin: a Receptor for SHetA2 
Benbrook et al. [80] applied an affinity chromatography combined with mass 
spectroscopy analysis to identify SHetA2 target protein(s). They synthesized a metabolite of 
SHetA2 by replacing the methyl group on the heteroatom ring with a hydroxyl group. This 
metabolite was attached to a long linker which then was conjugated to NanoLink Amino-
Magnetic Microspheres through an amide linkage. ShetA2-attached microspheres and free 
microspheres (negative control for non-specific binding) were incubated with the whole cell 
protein extracts from A2780 human ovarian cancer cell line. Microspheres were washed and then 
eluted with excess SHetA2. In SHetA2-conjugated microsphere, a band was observed around 75 
kDa. The specific bands excised from dried SDS-PAGE gels of the microspheres with and 
without SHetA2 and straight eluents were passed to QStar and Shotgun Orbitrap mass 




were identified in both mass spectroscopy analysis. Among which mortalin was significantly 
present in both experiments and was considered as the client protein for SHetA2.  Moreover, 
western  blot analysis of co-immunoprecipitates of mortalin with its client proteins in protein 
extracts from A2780 and SK-OV-3 human ovarian cancer cell lines revealed that SHetA2 binds 
to mortalin and disturbs the interaction of mortalin with p66shc and p53 in cancer cells. Protein 
p53 then translocates to mitochondria and nucleus, Bcl-2 degrades and p66shc is released and 
generates ROS. Thus, the SHetA2-Mortalin interaction affects intrinsic apoptosis induced by 
these molecules.  
Mortalin is a 73,913-kDa protein with 679 amino acids and a member of the heat shock 
protein (HSP) family. Heat shock proteins are ubiquitous, highly conserved proteins that are 
expressed constitutively and located in all cell compartments [88]. The role of HSPs in cell 
homeostasis was first observed by F. Ritossa when he found the overexpression of proteins of 70 
and 26 kD after exposing Drosophila larvae to heat stress [89]. In cancer cells, the conditions 
mimic stress thus HSPAs are upregulated.  
According to their molecular weight, HSPs are classified into several subfamilies among 
which HSP70 is the most important HSP involved in protein folding and tumor progression. 
Therefore HSP70 proteins are good targets for cancer therapy [90]. HSP70 subfamily consists of 
at least eight homologous chaperone proteins. Among which six are mainly located in cytosol and 
nucleus, the other two reside in endoplasmic reticulum (Grp78) and mitochondria (Grp75).  
Mortalin, is also known as glucose-regulating protein 75 (Grp75), mot-2, hmot-2, 
p66mot-1, mitochondria stress-70 protein (mtHSP70), HSPA9/HSPA9B, peptide-binding protein 
74 (PBP74), CSA, Mot, Mot2, and MGC4500. Mortalin was first cloned as an HSP70 family 
member in cytoplasmic of normal fibroblasts from CD1-ICR mouse [91, 92]. It was first 
identified as a cellular mortality factor as it was found present in cytosolic fractions of mortal 
cells while being absent in cytosolic fractions of immortal cells [91]. Immunocytochemical 




immortal cells and pancytoplasmic distribution of the protein in normal cells [93]. Thus, mortalin 
staining pattern is a sensitive marker of normal and cancerous cell types.  
It was shown that mouse has two types of mortalins; mot-1 and mot-2 alleles, which are 
assigned to chromosome 18 [92, 94]. These two types have different subcellular localization, 
secondary structures, and contrast functions although they only differ in two amino acids in 
carboxy-terminus; mot-1 has V618 and R624, and mot-2 has M618 and G624 [95]. These two 
residues are determinant factors in identifying secondary structure of mot-1 and mot-2. Mot-1 is 
originally cloned from normal cells, has pancytosolic distribution and is associated with 
senescence in NIH 3T3 cells [96]. Mot-2 however, is originally cloned from in immortal cells 
with perinuclear distribution [93] and is associated with malignant transformation of NIH 3T3 
cells [97]. Each of the two differentiating residues and three motif regions, thus the secondary 
structure of mot-1, can be essential in determining the ability to bind p53 in vivo [98]. Unlike 
mot-1, mot-2 binds to p53 in vivo, abrogates p53 nuclear translocation and inactivates p53 [98, 
99].  
Cloning of human mortalin cDNA from different cells showed that human mortalin has 
identical sequences with same functions as mot-2 in mouse [100]. Due to this similarity, it was 
first known as hmot-2.  
Human mortalin is translated in the cytoplasm and transported to mitochondria. Although 
mortalin is primarily found in mitochondria, it has also been found in several other subcellular 
sites including endoplasmic reticulum (ER), Golgi apparatus, plasma membranes, cytoplasmic 
vesicles, and cytosol [88].  
Mortalin is not a heat activated protein and can be induced by various stressors such as 
accumulation of unfolded or misfolded protein, low levels of ionizing radiation, glucose 
deprivation (GD), loss of calcium homeostasis, and metabolic stress [101-103]. Mortalin is also 




The three-dimensional structure of full-length mortalin is not available so far. Evolutional 
conservation suggests a similar structure for mortalin as other HSP70s. Mortalin has a conserved 
~42 kD nucleotide-binding domain (NBD, ATPase domain), residues 1-443 and a ~25 kD 
substrate-binding domain (SBD, peptide-binding domain as PBD), residues 444-697, joined by a 
highly conserved protease sensitive linker connecting them (Figure 4.8). The NBD consists of 
subdomains I and II, each dividable into a and b regions. The SBD can be further divided into two 
subdomains, the ~13 kD β-sandwich domain (SBDβ), consisting of 2 sets of 4-stranded 
antiparallel beta sheets and the ~12 kD C-terminal helical ‘lid’ domain (SBDα) consisting of five 
helices (A-E). The substrate-binding site is a hydrophobic region between the two β-sheets 
forming a deep binding pocket for hydrophobic residues. 
 
Figure 4.8 Structure model of full-length mortalin in ADP state constructed with I-TASSER 
server [106]. 
Known structures of NBD (PDB code 4HBO) and SBD (PDB code 3N8E) were used in 
construction of full length. 
 
NBD and SBD do not interact in ADP-bound state. In ADP-state, the lid covers the 
substrate-binding pocket in SBD and it opens up on exchange of ADP for ATP. In ATP-bound 
state, however the two domains are coupled [107]. As observed from the X-ray on Hsp110 [108], 
NMR on E.coli DnaK [109], and NMR on T. thermophiles [110], ATP binding induces the 
opening of polypeptide binding channel, thus facilitates the release of the substrate from SBD and 




and ATP hydrolysis [111] . Thus in an allosteric effect, binding of ATP improves the release of 
substrate while substrate binding increases the rate of ATP hydrolysis in NBD. Based on the 
narrow resonances in NMR TROSY spectrum, a flexible structure for the linker is suggested and 
it is assumed that linker region works like a switch and stimulates the ATPase activity [112].  
ATP hydrolysis provides the energy required for protein folding. However, some misfolded 
proteins cannot be recovered and need to be degraded. 
 
4.6. Protein p53 and its Interaction with Mortalin 
The homotetramer p53 is known as the “guardian of the genome”. It is a stress response 
factor that activates with intrinsic or extrinsic stress. Protein p53 consists of an amino-terminus 
transactivation domain (TAD residues 1-42), a proline rich domain (PRD 60-93), a sequence 
specific DNA binding domain (DBD or core domain CD residues ~100-300), and a C-terminal 
domain (p53CTD, residues 293-393) (Figure 4.9). CTD is the main site for protein-protein 
interactions. The p53CTD domain contains the tetramerization domain (TD residues 326-356) 
and the negative regulatory domain (p53NRD, residues ~361-393). Binding of proteins to 






Figure 4.9 (A) Structure model of full-length p53 constructed with I-TASSER server. (B) 
Domain structure of p53. (C) Tetramer model of p53 obtained by aligning the predicted full-
length model to the crystal structure (PDB code 2AC0) of four p53 DNA-Binding domains in 
complex with two DNA half-sites 
[114, 115]. 
Protein p53 is a nuclear transcription factor and controls cell cycle. To prevent genetic 
instability p53 induces cell cycle arrest (G1 arrest) and apoptosis as a response to endogenous and 
exogenous stress signals, through transcriptional regulation or direct interaction with apoptotic 
proteins [116]. Through its interaction with Bcl2 and mortalin, p53 regulates mitochondrial 
membrane potential [117]. Protein p53 is inactive in more than half of human cancers. 
Inactivation of tumor suppressor p53 is involved in transformation and immortalization of cells 
and is the most common genetically abnormality in human cancer. Three main mechanisms 
responsible for inactivation of p53 are mutations of p53, post-translational modifications, and 
cytoplasmic sequestration/nuclear exclusion [118, 119].  
Protein p53 is synthesized in the cytoplasm and translocated to the nucleus in order to 
perform its transcription factor function [120]. Cytoplasmic sequestration of p53 causes loss of 
the function and can lead to immortalization of cells and tumor resistance to radiotherapy and 
chemotherapy. The residues 323-337 of the carboxyl terminus of p53 were shown to be required 




to overexpression of its binding proteins, such as Bcl-2, PML, Parc [122] or mortalin [123-127], 
and cytoskeleton proteins . 
 Mortalin and p53 have been shown to colocalize in perinuclear region in several cancer 
cells, e.g. NIH 3T3, MCF7, COS7, NT-2, A172, A2182, HeLa, Balb/3T3, YKG-1, SY-5Y, and 
U2OS. Kaul et al. [128] showed for the first time that overexpression of mot-2 in normal human 
diploid fibroblasts (MRC-5) leads to decreased p53 function, thus temporary escape from 
senescence [128]. Also in human foreskin fibroblasta (HFF5) overexpression of mortalin together 
with telomerase hTERT extended lifespan substantially [129] indicating reduced p53 function. 
Life span extension of human lung fibroblasts (MRC-5), increased malignancy of human cancer 
cells [104], malignant transformation of NIH3T3 cells in mice [97], attenuation of HL-60 
leukemia cells by mot-2 [130] are some evidences that suggest the inactivation of p53 by 
overexpression of mortalin [97, 99, 128]. By interacting with the mitochondrial proteins Bcl2, 
mot-2, and HSP60, p53 regulates mitochondrial potential [117]. The stress-induced mitochondrial 
p53 localization is followed by changes in mitochondrial membrane potential, chromosome c 
release, procaspase-3 activation and apoptosis. The presence of mortalin-p53 complexes in 
mitochondria during p53-induced apoptosis suggests the transcriptionally independent role of p53 
in apoptotic signaling [131]. Different western blot patterns for mutant and wild type p53, 
suggested that loss of p53 function in human diploid fibroblasts transfected by mot-2, is not 
caused by mutation [128]. It is reported by the same group [98] that by sequestering p53 in the 
cytoplasm, mot-2 inhibits transcriptional activation function of the protein in mouse and human 
transformed cells. 
Regulatory function of p53 is independent of its localization and is performed by 
interaction of p53 with mortalin and Bcl2. Mortalin regulates the DNA-binding ability of p53 
[132].  
When binding to p53 in cancer cells, mortalin inhibits apoptotic properties of p53 and 




physical contact and blocks p53-mediated transcription, downregulates p53-target genes 
expression, e.g. p21SD11/WAF, and enhances degradation of p53 by MDM2 in cytoplasm, disturbs 
the G1-associated nuclear translocation of p53, that leads to uncontrolled cell proliferation, a 
hallmark of cancer cells [101, 121, 125]. Mortalin breaks the p53-Bcl-xL/2 complex and causes 
proteasomal degradation pathway of p53 by its association with E3 ligase CHIP (Carboxy 
terminus of Hsc70 Interacting Protein) [133]. Moreover, mortalin–p53 interactions causes 
deregulation of centrosome duplication, which is an indicator for cancer. Overexpression of 
mortalin can reverse the p53-dependent suppression of centrosome duplication indicating the 
interaction was localized to centrosomes [134]. 
It is shown that mortalin-p53 interaction depends on the stress levels in cells. In 
unstressed or weakly stressed cells, p53 and mortalin do not interact [127]. Thus, knock down of 
mortalin does not induce apoptosis. In contrast, in stressed cancer cells, whether physiologically 
stressed or under the effect of stress-inducing chemicals, mortalin-p53 interaction exists and 
knock down of mortalin induces p53-mediated apoptosis.  
Many studies has been performed to determine the binding sites of p53 and mortalin. 
However, the results do not identify the similar interaction sites. Carboxyl terminus of p53 was 
considered its cytoplasmic sequestration domain [99, 135]. This is in agreement with the 
previously shown results that breaking mortalin-p53 complex for example by p53 C-terminal 
peptides leads to restoration of p53 activities, abrogation of this cytoplasmic sequestration and 
relocation of p53 to the nucleus. Thus, the sequestration is reversible. 
Losefson et al. used the method of pull-down with heparin-sepharose beads to track p53-
mortalin interaction [132]. They found that this interaction is nucleotide sensitive and that in 
contrast with the result from cell lysates, the purified SBD of Mortalin, (and not NBD), binds to 
p53 in a concentration-dependent manor. They suggested that the contrast between in vitro results 
and results from cell lysate can be because of modifications or additional proteins in cell lysates 




One on TET domain and the other on CTD domain. Any of which is sufficient for binding. 
Another result was that the mutant p53 (L344P) which fails to form tetramer, binds to mortalin 
similar to the wild type tetrameric p53. Kaul et al. studied the effect of mortalin mutant in binding 
to p53 [98]. C-terminus deleted mutants represses p53 activity, suggesting that C-terminus of 
mortalin is not needed for interaction with p53. The mutation of V482F in the substrate-binding 
pocket abrogated the binding between mortalin and p53 [132], consistent with a similar mutation 
in DnaK, a bacterial homolog of mortalin, which also disrupts the substrate binding [136].  
Accordingly, pre-incubation of mortalin with a short substrate peptide greatly reduced its binding 
to p53 [121, 136]. The interaction between mortalin and full-length p53 can be abrogated by 
adding ATP [132]. All these evidences suggest that mortalin binds to p53 through its substrate-
binding pocket on SBD. However, so far, no direct evidence such as co-crystallization show the 
exact interacting domains between the two proteins. 
Gabizon et al. identified and characterized ten binding peptides by screening proteins that 
interact with tetrameric p53 C-terminal domain (p53CTD). They identified residues 266-280 in 
mortalin as the binding site for NRD (negative regulatory domain) of p53 [114]. 
In vivo co-immunoprecipitation of mortalin with p53 and its mutants in Human osteosarcoma 
(U2OS) and breast carcinoma (MCF7) cells revealed carboxyl terminus of p53 (resides 312-352) 
as the binding site for N-teminal region of mortalin mot2 [99, 125, 137].  
4.7. Protein p53-Mortalin Complex Inhibitors 
Mortalin-p53 complex is a selective target for cancer therapy [127]. Some short peptides 
[121, 135], small molecules, small interfering RNA (siRNA) [138], mortalin small hairpin 
shRNA (in hepatocellular carcinoma), UBXN2A (Ubiquitin-like (UBX)-domain-containing 
protein) can hinder p53-mortalin binding, reactivate p53 and induce apoptosis in cancer cells. 
             Some small molecule mortalin inhibitors include withanone [139] (a withanolide, one of 




(an anti-tumor compound, a water soluble delocalized lipophilic cationic/rhodacyanine dye 
analogue). Withaferin A (Wi-A) and Withanone (Wi-N) are two structurally similar withanolides. 
Wi-A is toxic to both cancer and normal cells, Wi-N however has milder effect and does not have 
toxic effects on normal cells. It suggests that Wi-N can be a safer cancer drug but higher doses 
are needed for the same effect as Wi-A. Mortalin was docked with both of these compounds and 
it was found that Arg513 in carboxyl terminus of mortalin interacts with them [143]. The result of 
our molecular modeling and NMR spectroscopy studies has confirmed the involvement of this 
residue in binding of mortalin and SHetA2. 
              Data shows stronger binding of Wi-A to mortalin. Wi-A and Wi-N also bonds with 
Arg282 and Leu111 residues of mortalin. Wi-A binds more effectively to p53. Attempts has been 
made to enhance the production of withanolides and elucidate their molecular mechanisms [144].  
              MKT-077 is selectively toxic to cancer cells and IC50 of MKT077 for normal cells is 
more than 100 times greater than that of cancer cell lines thus it was considered as cancer chemo-
therapeutic in a Phase I trial. However, the trial was stopped due to excessive renal toxicity in 
phase I clinical trials against solid tumors [145, 146]. MKT-077 interacts with HSPA8 [140] and 
HSPA9 [141]. The binding site of MKT-077 (positively charged) to HSPA8 ADP-state has been 
determined to be a negatively charged pocket close to residues in nucleotide binding site in the 
interface of subdomain Ia and IIa, which are 100% conserved between 13 human HSPAs [140]. 
The binding site of MKT-077 to HSPA9 is within residues 252-310, which in some studies is 
shown to include residues needed for binding of p53 [141]. Immunoaffinity studies showed that 
MKT-077 binds to mortalin at alpha-helix within sub-domain IIb of catalytic cleft and abrogates 
mortalin function, causes pancytoplasmic distribution of mortalin (characteristic of normal cells) 
and nuclear translocation and activation of p53. Thus induces growth arrest of cancer cells [141].  
               Molecular dynamic simulations and co-immunoprecipitation studies for both MKT-077 
and withanone ligands showed the abrogation of p53-mortalin interaction and re-activation of p53 




inhibit mortalin binding to p53. MKT-077 may inhibit binding of Tid1 by destabilizing the ATP-
bound conformation. Or it might inhibit binding of p53 by perturbing the conformation of 
mortalin at its β strand (residues 267-271) [147]. It is shown that growth arrest function of MKT-
077 is mediated by a p53-dependent pathway. In cancer cells, and not in normal cells, abrogation 
of p53-mortalin interaction leads to release of p53 from cytoplasm and translocation of p53 to 
nucleus and restoration of its transcriptional activation [141]. Similar effect for MKT-077 has 
been observed in a nonmammalian cancer model in soft shell clam Mya arenaria [126].  
 
4.8. Pharmocokinetics Studies 
SHetA2 absorption can be affected by factors like dose, species (thus different dietary 
habits, etc.), and formulation [148]. Effect of SHetA2 is time dependent and dose dependent. For 
example in ovarian cancer cell lines, cell cycle arrest contributes to SHetA2 growth inhibition, 
time-dependently and dose-responsively [149]. At lower concentrations, differentiation is 
observed however in higher concentrations apoptosis in dominate [57, 59]. Thus, it is important 
to determine concentrations, bioavailability, and stability of SHetA2 in order to measure the 
sufficient dosing of SHetA2 in clinical trials to target apoptosis inducing concentrations and 
maximize the activity of the drug.  
Kabirov et al. performed some preclinical pharmacokinetics to determine the 
toxicokinetics of SHetA2 in animals [67]. HPLC-UV studies have been applied and 
pharmacokinetic profile of SHetA2 has been obtained to quantify SHetA2 in plasma in mouse 
and human by Sharma et al. [150]. The result of a study performed by Zhang et al. [151] indicates 
a linear and predictive pharmacokinetics in mouse plasma. The terminal half-life, total body 
clearance value, oral absorption, and bioavailability were measured. This study also showed high 
tissue uptake. It measured the observed total body clearance of SHetA2 to be 1.81 l/h/kg and 




Liu et al.[152] applied liquid chromatography-ultraviolet/multi-stage mass spectrometry 
(LC-UV/MSn) to evaluate SHetA2 metabolites in human and rat liver microsomes in vitro and in 
mice and rats in vivo.  
In another study Sharma et al. [153] developed a novel method for quantification of 
SHetA2 in human and mouse plasma. In this HPLC-UV bioanalytical method, lower limit of 
quantification (LLOQ) is =5 ng/ml and lower limit of detection (LLOD) is 2.5 ng/ml, which was 
lower than previous study in which LLOQ was 10 ng/ml, thus this method has higher sensitivity. 
Moreover, this method showed specificity, accuracy, precision, stability, and reproducibility.  
It appeared that once the absorption saturation reaches, increasing doses will decrease 
bioavailability and absorption [81] for higher doses. Absorption saturation in mice, rats and dogs 
is about 100 mg/kg body weight/day [67, 151, 152]. 
             Highly hydrophobic SHetA2 has low water solubility and low gastrointestinal (GI) 
absorption, and expressed low oral bioavailability in rats (<1%) and dogs [67]. In dogs, 
suspension of SHetA2 in 30% aqueous Kolliphor HS15 enhances the bioavailability.  
             Optimal dose is a dose at which chemoprevention occurs without toxicity. The dose that 
reduces cyclin D1 in neoplastic and not in normal cells. The AIN76A diet formulation of 
SHetA2, 187 mg/kg/day SHetA2 suspended in Kolliphor HS15 for bioavailability enhancement 
has been reported in mice and effective tissue drug levels was observed at this dose with no 
toxicity [81]. SHetA2 showed very low toxicity, with a no-observed-adverse-effect level 
(NOAEL) of 500 mg/kg/day in rats and over 1500 mg/kg/day in dogs [67]. Based on 
bioavailibility-dose studies NOAEL in human dose was chosen 100 mg/kg [153]. On the other 
hand, the oral administered dose of SHetA2 that reduces the colon and small intestinal polyps 
incidence and sizes is 30 mg/kg/day [71]. While a dose of 10 to 60 mg/kg/day can inhibit 
xenograft tumor growth [25, 62, 67]. This large therapeutic window makes SHetA2 an ideal 




Responses to SHetA2 doses in APCmin/+ Mice was found to be gender related. This suggests that 
male and females to be dosed differently [71].Some administration routes of SHetA2 include oral 




SHetA2 is a Flex-Het with promising anti-cancer activities. It contributes in both intrinsic 
apoptosis by directly targeting mitochondria associated with reduction of Bcl-2, and extrinsic 
apoptosis by enhancing death receptor activation through inhibition of nuclear factor κB (NF-κB) 
and inducing the expression of the CHOP protein. SHetA2 reduces the expression of Bcl-2 in 
cancer cells thus promotes apoptosis [60, 62] while mortalin can prevent this effect leading to 
inhibition of apoptosis. Thus Mortalin and SHetA2 can regulate the Bcl-2 protein family and 
affect the stability of mitochondria.  
Inactivation of p53 through its interaction with mortalin, can disturb p53 apoptosis 
function. Once p53 is released from the complex with mortalin, it can translocate to the nucleus 
where it induces multiple genes that contribute to apoptosis. The interaction between the two 
proteins can be disturbed by SHetA2. SHetA2 abrogation of mortalin binding to p53 augments 
SHetA2 induced apoptosis.  
SHetA2 has low water solubility. In chapter 7 and 8 we study SHetA2 analogs with the goal to 






NMR STUDIES OF THE INTERACTION BETWEEN MORTALIN AND SHETA2 
 
5.1. Introduction 
As mentioned in the previous chapter, Heat shock protein HSPA9/mortalin interacts with 
the tumor protein p53 and is also a client for SHetA2. Mortalin sequesters p53 in cytoplasm and 
hinders its apoptotic function. Binding of SHetA2 to mortalin will interrupt p53-mortalin 
complex, and releases protein p53 to nucleus where it initiates apoptosis. Thus, one pathway for 
the compounds to inhibit the growth of cancer cells in vitro is by displacing p53 from mortalin. 
However, interactions of mortalin with other client proteins, such as Bcl-2 and p66shc, may also 
affect cell apoptosis. 
The substrate-binding domain (SBD) of mortalin was shown to associate with the tumor 
protein p53 in a concentration-dependent manner [27]. A mutation of V482F in the substrate-
binding pocket abrogated the interaction with p53 [27], consistent with a similar mutation in 
DnaK, a bacterial homolog of mortalin, which also disrupts the substrate binding [136]. 
Moreover, pre-incubation of mortalin with a short substrate peptide greatly reduced the 
interactions between mortalin and p53 [136]. These are some evidences that suggest that p53 





In this chapter, we study the interaction of the mortalin substrate binding domain (Protein 
Data Bank ID: 3N8E) with SHetA2 via solution NMR. We use chemical shift perturbation 
experiments to study these interactions. 
 
5.2. Materials and Methods 
5.2.1. Chemicals and Reagents 
Purified SHetA2 powder is kindly provided by Dr. Berlin. Plasmid pET-52 with Mortalin 
SBD (AA#439-597) encoding gene is kindly provided by Dr. Benbrook. Lysozyme was 
purchased from MP Biomedicals (Santa Ana, CA). Benzonase was purchased from Semba 
Biosciences (Madison, WI). Protease inhibitor cocktail, ampicillin, kanamycin, imidazole, biotin, 
DTT, chloramphenicol and other chemicals were purchased from Sigma-Aldrich (St. Louis, MO). 
Isotope-enriched (13C, 15N) ISOGRO supplement, 15NH4Cl and uniformly labeled 13C glucose 
were purchased from Cambridge Isotope Laboratories (Andover, MA). The Profinity™ IMAC 
Nickel Charged Resin was purchased from Bio-Rad Laboratories (Hercules, CA). Thrombin is 
purchase from Bio Pharm Laboratories (Alpine, UT). Ni-NTA purification kit is purchased from 
Bio-Rad (Hercules, CA). 
 
5.2.2. Sample Preparation  
A. Protein expression and purification 
The mortalin SBD encoding gene was introduced into pET-52 vector through NcoI and 
BamHI double restriction cleavage sites with a customized stop codon right after the sequence. 
The recombinant protein was constructed with 10×His tag on the N terminus, a HRV-3C protease 
cleavage site (LEVLFQ/GP), and a linker (SGPASPR). The theoretical pI of the recombinant 
protein after treatment with HRV-3C protease is 5.31 and molecular weight (MW) is 18129.47 




(DE3) competent cells. The glycerol supplemented stock cells were prepared and stored in -80°C. 
5 μl of transformed cell stock was then spread on an ampicillin treated Lauria agar plate, 
incubated overnight at 37°C. A colony was transferred to 100 mL ampicillin supplemented LB 
medium and incubated at 37 °C, 250 rpm until optical density at 600 nm (OD600) reaches 0.8 or 
overnight. The cells were pelleted at 4000 rpm for 20 min, the pellet was re-suspended in 5 times 
volume of 13C-glucose and 15NHCl4 supplemented M9 medium (Table 5.1) . The culture was 
incubated at 37 °C 250 rpm until OD600 reaches 0.8. Final concentration of 1 mM IPTG was 
added and the cells were induced at 20°C, 250 rpm for 20 hours. The cells were then harvested by 
centrifugation at 4000 rpm for 30 minutes. The cell pellets were re-suspended in the lysis buffer 
(Table 5.2). Lysozyme was added to a final concentration of 0.5 mg/ml. DNase was added to 
reduce viscosity and clumpy cell suspension. 1 mM tris (2-carboxyethyl) phosphine (TCEP) and 
1 protease inhibitor cocktail (to prevent protein degradation) was added. We then either 
vortexed the cells every 15 minutes for 1 hour on ice or put on rocker at 4°C for 2 hours. The 
lysed cells were sonicated and centrifuged at 30,000 kg for 40 min at 4°C. The protein is in the 
supernatant. The supernatant was filtered by a 0.2 μm pore size filter to remove any remaining 
cells for the next step, that is protein purification. The supernatant was incubated with Ni-NTA 
resin for 1 hour at 4ºC and loaded onto a column. In parallel, the column was washed with Buffer 
B (20 mM Tris, 500 mM NaCl, 250 mM Imidazole, at pH 7.8),  water, and Buffer A (20 mM 
Tris, 500 mM NaCl, 20 mM Imidazole, at pH 7.8). The resin-supernatant mixture was then 
loaded on the column. The flow through, wash and elute eluents were collected. The column was 
washed with 10 CV Buffer A and eluted by 10 CV Buffer B and then Buffer C (20 mM Tris, 500 
mM NaCl,  1M Imidazole, at pH 7.8). The eluents were run on a SDS page gel to identify the 
eluent(s) containing the protein. Next, the protein-containing eluents were cleaved by HRV-3C 
protease to remove His-tag and buffer exchanged to dialysis buffer via dialysis overnight. 




equilibrated with Ni-NTA resins for 1 hour at 4ºC and loaded on to the second Ni column to 
remove the cleaved His-tag. The goal is to have the final sample in the dialysis buffer. FT eluent 
was collected. Then the column was washed with 5 CV of wash-I (with Buffer D), followed by 5 
CV of Buffer A, 5 CV of Buffer B, and 5 CV of Buffer C. The protein is mostly in FT and some 
in wash I. SDS-PAGE was run to test the purity of the protein. We centrifuge the sample to the 
desired concentration for NMR (~10-20 mg/ml) and stored at 4 °C before use. In case of the need 
for longer term storage, samples should be flash freezed and store at -80°C.   
 
Table 5.1 Supplemented minimal growth media (M9) 
 for 13C,15N-labeled protein expression. 
 
M9 (1L)  
5x M9 salts 200 ml 
13C-glucose  2 g 
15NH4Cl 2 g 
1000x Ampicillin  1 ml 
Biotin 8 mg 
100x BME 10 ml 
100x Thiamine 1 ml 
MgSO4(1M) 400 μl 
CaCl2(1M) 40 μl 
FeCl3(.01M) 200 μl 







Table 5.2 Lysis buffer composition 
Lysis buffer for 1L of cells  
20 mM Tis, 500 mM NaCl, pH=8.0 24 ml 
50 mg/ml Lysozyme 480 μl 




 Figure 5.1 SDS-PAGE of purified Mortalin and digestion by HRV 3C protease.  
The lane on the left is the marker proteins with molecular weight labeled. The lane in the middle 
shows the protein after treated with HRV-3C and removal the His-tag. The right lane is the 
purified protein through Ni-NTA. 
 
B. NMR Sample Preparation  
SHetA2 is water insoluble therefore we dissolved SHetA2 in DMSO and used the dissolved 
SHetA2 sample for titration with the protein sample. To prepare the ligand sample we dissolved 
4.5 mg SHetA2 into 25 μl DMSO. This gives a 180 mg/ml or 420 mM concentration sample 
consistent with our previous tests. Protein sample was prepared with adding 450 μl protein 




μl D2O (10% D2O). D2O is added to lock the NMR signals. The ligand sample was then titrated 
into the protein sample to make our NMR samples. Molar ratio of protein to ligand was 1:0.2, 
1:0.4, 1:0.6, 1:0.8, 1:1, 1:2, 1:4, 1:8, and 1:16. In one tube, we had the protein sample which we 
titrated with ligand sample, and in the other tube we had the protein sample titrated with DMSO 
as control. The same NMR experiments with same parameters were performed on both samples. 
5.2.3. NMR Spectroscopy 
NMR experiments were performed at 25 ºC on a Agilent INOVA 600 MHz spectrometer 
with a Nalorac 5-mm 1H, 13C, 15N PFG triple resonance probe and VnmrJ software with Biopack 
suite of pulse programs to collect the data. A 1D experiment was performed to have a quick check 
on the status of the sample and the signal. If desired quality is observed, then a 2D 15N–
heteronuclear single quantum coherence (NHSQC) is acquired to further check the protein sample 
quality. HNCA, HNCOCA, HNCO, HNCACO, HNCACB, and HNCOCACB spectra are 
collected for backbone assignment and CCONH and HCCONH for side chain assignment. 
NMR spectrum were collected and data were processed using NMRPipe [156], a 
software for processing and analyzing multidimensional NMR spectroscopic data. The processed 
data from NMRPipe was then used as the input for SPARKY [157], a graphical interface that is 
used to assign, pick, and integrate NMR peaks of macromolecule. Output of the SPARKY is text 
peak lists with assignments, chemical shifts, linewidth, etc. Then the sequence of the protein and 
the spectral peak list were uploaded to the PINE server [158]. Then we explored the auto-
assigned spectra in SPARKY and made some controls and corrections. The data was then 
analyzed with TALOS+ [159], a software in NMRPipe software package that predicts the 
secondary structure by establishing a relation between 13C, 15N and 1H chemical shifts and 
backbone dihedral angles ϕ and ψ. 
The chemical shifts were assigned to each individual amino acids. The chemical 





𝛿 = 𝛿 − 𝛿 + 10 × 𝛿 − 𝛿  (5.1) 
where the δNl and δHl are the 15N and 1H chemical shift difference between the last SHetA2 
titration and apo-state. The δNs and δHs are the 15N and 1H chemical shift difference between the 
corresponding last DMSO titration and apo-state.  
 
5.3. Result and Discussion 
5.3.1. Solution NMR of Mortalin SBD and Backbone Assignments 
The NMR sample was loaded into a 5 mm solution NMR tube. A 1D experiment was 
performed to have a quick check on the status of the sample and the signal. If desired quality is 
observed, then a 2D 15N–heteronuclear single quantum coherence (NHSQC) is acquired to further 
check the protein sample quality (Figure 5.2). In NHSQC one axis is proton 1H and the other is 
the heteronucleus N. Through J coupling magnetization is transferred from H to the attached N, 
and then transfers back to the H and will be detected. The NHSQC spectrum mainly shows the 
backbone amide H-N correlations. Well dispersed peaks with proton chemical shifts spreading 
around 7 ppm to 9.7 ppm is an indicator of a well-folded protein and we can continue acquiring 
further NMR spectrum which includes sequential 3D backbone assignments experiments i.e. 





Figure 5.2 2D 1H-15NHSQC spectrum  
of the labeled mortalin sample with assignments.  
 
Pairs of two complementary 3D NMR (or triple resonance) spectrums, HNCA-HNCOCA, 
HNCO-HNCACO, and HNCACB-HNCOCACB are acquired to obtain sequential 3D backbone 
assignments. HCCONH-CCONH pair of spectrum can give more side chain residues assigned. 
The peaks in NHSQC were selected and used as the guiding position for peak selection in the 3D 
data set. The HNCA, HNCACO and HNCACB correlates inter- and intra-residues, while 
HNCOCACB, HNCOCA and HNCO only give the intra-residue correlation. HNCACB for 
example gives the chemical shift information for each amide of residue i and the chemical shift 
information of the alpha and beta carbon of residue i and i-1. Thus, HNCACB correlates each NH 
group of residue i with the Cα and Cβ chemical shifts of residue i and Cα and Cβ of residue i-1. 
HNCOCACB however give the chemical shift information for each amide of residue i and only 




of Cα and Cβ chemical shifts are characteristic of the amino acid type. Then the assigned chain 
can be matched to the sequence of amino acids in the protein. Resonances within a residue and 
between neighboring residues allows for complete chemical shift assignment through backbone 
walk. In Figure 5.4 the HNCACB and HNCOCACB spectra for residues 102 to 106 are 
displayed. Each HNCACB slice has the Cα and Cβ from residue i and the Cα and Cβ from 
residue i-1 and each HNCOCACB slice has two Cα and Cβ peaks from residue i. All there peaks 
can be correlated through backbone walk. 
 






Figure 5.4 The backbone assignments example. 
 
The peaks positions and intensities data were uploaded to the PINE server 2.0 for auto-
assignment of the peaks. The assignments are then inspected manually for control. The output 
result has 90% confidence in assignment (Figure 5.5). Secondary structure probabilities are 
predicted using PECAN automated tool [160] from the chemical shift assignments with good 




for probabilistic secondary structure determination. The output obtained from PINE server is 
submitted to PECAN. Input of PECAN has BMRB format. 
 
 
Figure 5.5 Assignments prediction probabilities for each amino acids in mortalin obtained from 
the I-PINE server.  
Green shows 100% confidence, Yellow-green indicates over 90% confidence, Cyan means over 
80% confidence, Yellow shows 50%, and Red is less than 50% confidence. 
 
 
Figure 5.6 Probabilities of the secondary structure predictions obtained using PECAN. 
The length of each bar represents the probability. 
 
We can predict the secondary structure by TALOS+ also as it is shown in Figure 5.7. The 
predicted order parameter S2 (upper window) and ANN-predicted secondary structure (lower 
window) plotted for all residues are shown. The predictions have high overall confidence and 




confidence in the both ends is because these parts are flexible regions in solution. In the crystal 




Figure 5.7 Secondary structure predicted by TALOS+.  
Aqua bars represent β-sheets and red bars represent helices. The height of the bars is a measure of 
the probability of the prediction. 
 
5.3.2. Chemical Shift Perturbation 
Chemical shift perturbation information are used to identify protein-ligand binding sites. 
Peak shifts following the titrations indicate conformational changes of the protein upon binding 
of SHetA2. NHSQC spectrum was acquired for the apo-state protein sample (without SHetA2) 
and titrated SHetA2 sample (Figure 5.8). The protein backbone resonance peaks in the NHSQC 
spectrum were affected by SHetA2 titration. The top most affected shifts are L457, V471, S473, 





Figure 5.8 Peak shifts caused by adding SHetA2.  
Different colors indicate different molecular ratio of protein:SHetA2. (Red 1:0, yellow 1:0.4, 
green 1:0.8, blue 1:2, purple 1:8) 
 
The chemical shift perturbation plot is found from eq. 5.1 and plotted in Figure 5.9. The 
height of the bar is indicative of the relative chemical shift changes of SHetA2 titrated spectrum 
from DMSO titrated spectrum. These residues form the binding pocket for SHetA2 in substrate 
region of mortalin. Our NMR spectroscopy data together with the result from our molecular 
dynamic studies identifies this binding site to overlap with the binding site of p53 to mortalin. 





Figure 5.9 Chemical shift perturbation of mortalin  





The top 11 residues which had the most significant chemical shifts are obtained from chemical 
shoft assignments and been plotted using VMD Figure 5.10.  
 
Figure 5.10 The most shifted peaks  
upon binding of SHetA2 are shown in the substrate binding domain of mortalin  
 
As it is observed in Figuer 5.10 the top shifted peaks are L457, V471, S473, A475, G514, V515, 
I518, D572, K576, V579 and E586. These include residues on a hydrophobic pocket in SBD and 
some residues on the lid helix. 
 
5.4 Conclusion 
The predicted structure from chemical shifts has high similarity to the crystal structure 
except the more flexible unstructured C-terminus. We investigated the interaction of mortalin 
with SHetA2 using solution NMR. From the chemical shift perturbation data, we observe that 
SHetA2 binds to a binding pocket in the substrate binding domain of mortalin which in some 
studies has been shown to be the binding site for p53. Thus, the competitive binding of SHetA2 
and p53 to mortalin can disrupt the interactions between p53 and mortalin and release p53. We 
identified the most perturbed residues upon binding. Among which some form a hydrophobic 
pocket within the SBD. This suggests the importance of hydrophobicity in the binding pocket . 




the effect of increasing hydrophobicity on the binding strength by designing novel analogs of 
SHetA2. NMR spectroscopy results can identify the strength of binding (Kd), site of interaction 
and residues involved in the binding to ligand. Thus NMR spectroscopy can help designing of 







MOLECULAR DYNAMICS STUDIES OF MORTALIN-SHETA2 USING GROMACS 
 
6.1. Introduction  
Molecular Modeling has vast applications in drug discovery and design. It provides a fast 
and powerful tool to investigate the interactions between protein and ligand. The result however 
needs to be validated and optimized by incorporating experimental findings. We applied 
molecular docking and molecular dynamics tools to investigate mortalin-SHetA2 interactions. 
We found the binding configurations and affinities of the complex and provide some evidence 
that the interaction between mortalin and SHetA2 can abrogate mortalin-p53 binding. More 
details on our studies in molecular docking approach is presented in chapters VII and VIII. In this 
chapter, we emphasize on molecular dynamic studies of the wildtype and mutant mortalin in 
complex with SHetA2 using GROMACS. 
 
6.2. Material and Methods 
The crystal structure of protein, mortalin (PDB ID: 3N8E), was downloaded from Protein 
Data Bank. VMD [161] mutator was used to generate protein mutants. To include the ligand 
topology, the ligand.itp file is needed. First ChemSketch™ (Advanced Chemistry Development, 
Inc. ADC/Labs, Toronto, Ontario, Canada) was used to generate the SMILES notations which 




GUI [162]. Next the ligand.pdb file was converted to ligand.mol2 using UCSF Chimera 
[163]. This was achieved by submitting ligand.mol2 to swissparam server, 
http://www.swissparam.ch/. The ligand.pdb and ligand.itp were included in system topology file. 
System preparation, some of simulations, and final analysis were performed on an iMac with a 
2.4 GHz Intel Core i3 processor and 4 GB RAM. The main molecular dynamics simulations were 
performed at the OSU High Performance Computing Center at Oklahoma State University 
supported in part through the National Science Foundation grant OAC–1126330. The Cowboy 
linux cluster has 252 standard compute nodes, each with dual Intel Xeon E5-2620 “Sandy 
Bridge” hex core 2.0 GHz CPUs, with 32 GB of 1333 MHz RAM. We used software GROMACS 
4.5.5 [20] and CHARMM27 sets of force field with tip3p water model [164]. Ligand topology 
was created with swissparam and was included in the system topology. Periodic simulation box 
was defined to mimic the infinite system to avoid real phase boundaries and to minimize finite 
boundary effects. Distance of the complex from the walls of the box was at least 1.5 nm. The box 
was filled with water and 100 mM of NaCl was added to mimic the experimental condition, under 
which we performed NMR experiments. The initial energy minimization was then performed by 
using steepest descent algorithm until the system converges to a minimum energy with forces less 
than 100 kJ/mol/nm (emtol=100 kJ/mol/nm).  
The following equilibrium step was conducted in two phases, constant volume (NVT) 
and constant pressure (NPT). Each with 1 fs time steps for 5 and 10 ns respectively. NVT is 
performed to ensure that the average temperature of a system is correct (300 K in this 
experiment). In NVT equilibration the system was strongly coupled to a temperature bath using 
V–rescale coupling [165] with coupling constant of T = 0.1 ps. Equilibration of pressure is done 
during the NPT phase to maintain the pressure isotropically at 1 bar. A strong Parrinello–Rahman 
pressure coupling with time constant P = 5.0 ps was used [166], as well as a weak Nose–Hoover 




After equilibration, 100 ns production run of molecular dynamics was performed in 2 fs 
time steps with weakly coupled temperature and pressure (Nose–Hoover T = 0.5 ps and 
Parrinello–Rahman P = 2 ps). Leap–frog integrator [170] was applied during NVT, NPT, and 
MD simulations. During the MD run, system coordinates, velocities, trajectories and energies 
were recorded every 2 ps. Cut-off distances including neighbor list, electrostatic, and van der 
Waals cut-offs were 1.2 nm. The Lennard–Jones potential is used to estimate the non–bonded van 
der Waals interactions, and Particle-Mesh Ewald (PME) algorithm is used for long range 
electrostatic interactions treatment [171]. The bonds were constrained by LINear Constraint 
Solver (LINCS) algorithm [172].  
 
6.3. Results and Discussion 
Binding of mortalin to p53 causes cytoplasmic sequestration of p53 thus loss of the 
function of p53 and leads to immortalization of cells and tumor resistance to radiotherapy and 
chemotherapy. Thus abrogating this binding is important in re-locating p53 to the nucleus where 
it re-gains its apoptosis functions. Identifying the binding site of mortalin with p53 gives insights 
on identifying the complex inhibitors, which can potentially have anticancer effects. As 
mentioned in chapter 4, several studies have been performed to identify the binding site of p53 
and mortalin. Some identified NBD and some identified SBD as the binding domain on mortalin. 
Our result from molecular dynamic simulations, showed both bindings are possible. (Result from 
NBD domain is not included in the current paper). 
MD simulations was carried out for 50 ns followed by distant calculations. The 





Figure 6.1 SBD mortalin – SHetA2 complex lowest bonding energy frame in 50 ns MD 
simulations using GROMACS and visualized by VMD. 
(A) Surface display and (B) Secondary structure display of mortalin SBD and Surface display of 
hydrophobic binding pocket  
 
It is observed that SHetA2 is located within a hydrophobic binding pocket in SBD 
mortalin, surrounded by ILE447, THR449, LEU450, PHE472, SER473, THR 474, ALA475, 
VAL482, ILE484, GLY514, ILE518 residues. These residues are shown in the Figure 6.1. 
Moreover, backbone oxygen atom of S473 and T474 form hydrogen bonds with the nitrogen 
atoms in the ligand (Tables 6.4 and 6.5) and positively charged R513 have electrostatic 
interaction with NO2 group of the SHetA2. 
We performed several mutations on mortalin SBD to identify the essential residues 
involved in the binding. Including substrate binding domain residues R513E, S473A, T449A, and 
V482F. Among which we mention V482F in this paper. 
In the case of V482F, similar mutation in DnaK, a bacterial homolog of mortalin, 
suggested defective interactions with substrate binding proteins [136] thus it is expected to be the 
case in moratlin SBD as well. Experimental results from also show this mutation abrogates p53-
mortalin interaction [173]. We calculated the binding energy using GROMACS and g_mmpbsa 
tool to investigate the effect of this mutant. The structure of the wild type and mutant protein in 






Figure 6.2 WT and mutant SBD mortalin in complex with SHetA2 after 50 ns MD simulations 
using GROMACS and visualized by VMD 
(A) SHetA2 in the binding pocket of the WT protein-Front view 
(B) SHetA2 in the binding pocket of the mutant protein (V482F)-Front view 
(C) SHetA2 in the binding pocket of the WT protein-Side view 
(D)SHetA2 in the binding pocket of the mutant protein (V482F)-Side view 
 
In the front view is observed that in the mutant protein ring A of the ligand is pushed 
down, away from F482 and closer to L450. In the side view we can see ring A is now further 
from R513.  
Considering the previously found results that showed V482F mutation breaks the 
interaction of mortalin and p53 and the result from our simulation studies that revealed the 




both p53 and ShetA2 interactions with mortalin. SHetA2 may compete with p53 to bind to 
mortalin and abrogate their interactions.  
Using g_mmpbsa, we performed energy calculations for the ligand-protein interaction 
after MD simulations on protein-ligand for 50 ns. Table 6.1 contains several lowest energy 
residues sorted based on mechanical energy with the corresponding energy terms of MM, polar, 
nonpolar, and total energy in kJ/mol. The only difference seems to be Arg 513 which is among 7 
lowest energy residues in wildtype SBD and is absent from the list of lowest residues for the 
V482F mutant. And the Gly 451 which is one the lowest energy residues in the mutant and is not 
among the 7th lowest energy residues of wildtype. R513 is no longer reachable because the NO2 
of SHetA2 gets distance from R513 when the other end of the molecule is pushed down by F482 
in the mutant. 
Table 6.1 Residue-wise contribution to different energy terms 








(kJ/mol)   
Apolar 
Energy 




ALA-475 -7.2900  1.1470 -0.3170 -6.4600 
ARG-513 -7.3290 7.0320 -0.5420 -0.8390 
THR-449 -7.9330 3.4610 -0.3430 -4.8150 
PHE-472 -9.8360 1.3820 -0.5480 -9.0020 
SER-473 -10.2440   9.4460 -0.7880 -1.5860 
THR-474 -10.3930   5.5310 -0.1360 -4.9980 











(kJ/mol)   
Apolar 
Energy 




GLY-451 -6.8240  4.5710 -0.7830  -3.0360 
THR-474 -7.0700  4.1320 -0.1520  -3.0900 
ALA-475 -8.8400  3.2710 -1.3340  6.9030 
THR-449 -9.4750 4.8310 -0.1110 -4.7550 
SER-473 -10.4920   5.2010  -0.7410 -6.0320 
PHE-472 -10.7700   2.4760  -0.3520  -8.6460 
LEU-450 -17.3880  5.3920 -0.9520 -12.9480 
 
EMM is the molecular mechanics potential energy in vacuum and includes both bonded (such as 
bond, angle, torsion energies) and nonbonded terms (such as van der Waals ad electrostatic 
interactions). Moreover, polar and apolar energy terms are the components of free energy of 
solvation. 
In Table 6.2, average binding energy of the two systems (wild type and mutant) is listed along 









Table 6.2 Comparison of different energy terms 




Van der Waal -175.869±10.327 -206.796±11.723 
Electrostatic -13.497±10.327 -18.579±2.235 
Polar Solvation 75.476±5.089 105.476±10.483 
SASA -17.821±0.772 -20±167 
Binding Energy -131.711±10.096 -140.066±10.954 
Solvent Accessible Surface Area (SASA) is a model that is used to estimate nonpolar solvation 
energy counting for the repulsive(Gcavity) and attractive (Gvdw) forces between the solute and the 
solvent upon the formation of the cavity.  
The lowest energy frame has been obtained from the trajectory file of the system and the 
corresponding energy of that frame is calculated to be -167.901 kJ/mol for the wildtype and -
182.956 kJ/mol for the V482F mutant. As listed in table 6.3 along with the average energy of the 
system. 
Table 6.3 Binding Energy comparison 
 WT kJ/mol V482F 
Min BE -167.901 -182.956 





Table 6.4 contains percentages of the time when hydrogen bond is formed between the 
specific acceptor/donor partners. For example more than 90% of the whole simulation time, a 
hydrogen bond is formed between the carbonyl group of T474 and N1 nitrogen atom of SHetA2 
linker while no hydrogen bond was observed to be formed between the T474 and S473 residues 
in V482F. 
 
Table 6.4 Hydrogen bonding comparison 
Lig_N and Lig_N1 are the two nitrogen atoms in SHetA2 thiourea linker, with N being the atom 
closer to the double ring. 
Acceptor/Donor WT V482F 
S473_CO_Lig_N 51.0% 0% 
S473_CO_Lig_N1 2.14% 0% 
T474_CO_Lig_N 30.06% 0% 
T474_CO_Lig_N1 92.76% 0% 
 
The distance between the H-bond participant atoms is calculated at the lowest binding energy 









Table 6.5 Distance (nm) at the point of min BE  
Acceptor/Donor WT V482F 
S473_CO_Lig_N 0.314 0.369 
S473_CO_Lig_N1 0.408 0.343 
T474_CO_Lig_N 0.332 0.374 
T474_CO_Lig_N1 0.310 0.469 
The difference in binding energies of the mutant and WT can have different reasons. One 
reason can be that phenylalanine contains a highly hydrophobic benzene ring so the contribution 
of this residue to the binding energy is higher in the wildtype. Also the ligand gets closer to the 
Leucine 450 and this can explain the increased contribution of this residue to the MM energy in 
the mutant, thus the increase in total binding energy of the mutant. 
 
6.4. Conclusion 
We identified the binding configurations and the interacting residues of mortalin with 
SHetA2 using MD simulations. Mutations in the protein sequence can alter the binding 
configuration and the binding energies. We studied V482F mutation in this study. Energy 
calculations have been performed on both mutant and wild type protein and the result have been 
compared. The bulky side chain of phenylalanine at position of amino acid 482 tends to 
significantly reduce the available space in the hydrophobic pocket. Thus, the ring A of SHetA2 is 
pushed down and away from the bulky F482. Ring B (containing NO2) gets tilted away from 




to Phenylalanine breaks the hydrogen bonds that was formerly observed between T474-LigN,N1 
and S473-LigN,N1.  
Considering the previously found results that showed V482F mutation breaks the 
interaction of mortalin and p53 and the result from our simulation studies that revealed the 
change in the conformation of SHetA2 in the binding pocket, it appears V482 can be involved in 
both p53 and ShetA2 interactions with mortalin. SHetA2 may compete with p53 to bind to 











The currant chapter is an overview of our published paper on the novel activity of 
oxygen- versus sulfur-containing analogs of the SHetA2.  
As our results from molecular mechanics studies suggests, hydrophobicity of the ligand is 
an important factor in its binding performance. Thus, we propose several analogs for SHetA2 and 
investigated the effect of hydrophobicity on their efficacy and potency. In addition, to determine 
if certain fragments of the lead molecule SHetA2 could be modified to enhance aqueous 
solubility, targets were synthesized with an oxygen-containing chroman unit, in place of the 
thiochroman, and both urea and thiourea containing compounds were studied. The aim of this 
work was to develop synthesis of oxygen counterparts of SHetA2 (structures 2-8 in Figure 7.1), 
with sufficient structural diversity to allow a modest structure-activity relationship (SAR) 
analysis of this family of structures. Five series of chromans with urea and thiourea bridges 
connecting a chroman unit (ring A) and a single 4-substituted benzene unit (ring B) have been 
prepared and evaluated relative to SHetA2 for activity against the human A2780 ovarian cancer 
cell line. Substituents on the chroman unit were modified to appraise the importance of 




The 2-Me-4-Me series (two sets of geminal dimethyl groups at C2 and at C4 on the ring A unit) 
permitted direct comparison with SHetA2. Ring B in this series was evaluated with specific 
functional groups at C4 on the ring, including NO2, CO2Et, CF3, OCF3, CN and SO2NH2. 
The 2-H-4-Me series (only one geminal dimethyl group at the C4 position on ring A) permitted 
structure-activity relationship analysis to relate the critical importance of the hydrophobic 
geminal dimethyl groups on ring A to the activity of SHetA2.  The remaining three series 2-Et-4-
Me, 2-Me-4-Et and 2-Et-4-Et (ring A methyl groups replaced with ethyls at C2, at C4 and at both 
C2 and C4, respectively) offered the opportunity to modulate the hydrophobicity of the chroman 
moiety. Additionally, in all these series, the influence of a urea versus a thiourea bridge was also 
investigated.  The results of these modifications are summarized below.  The exact analog of 
SHeA2 with oxygen substituted for sulfur in ring A (2a) showed comparable efficacy but a 
significant reduction of inhibitory prowess against the ovarian cancer cell line.  However, the urea 
bridged analogues bearing CF3, CN, and OCF3 at C4 of ring B (3c, d, and f) had higher IC50 
values and greater efficacy than SHetA2. Removing the geminal dimethyl group at C2 (4a-c, 5a-
c) caused a significant lowering of the efficacy and the percent of growth inhibition for all of the 
derivatives screened, indicating that the hydrophobic geminal dimethyl group at C2 in ring A is 
crucial for activity.  In general, ethyl groups at C2 and C4 of ring A improved potency of the 
compounds. Replacing the geminal dimethyl groups with geminal diethyls on ring A in the urea 
derivatives gave 6b-c, 7c-d and 8b, all of which outperformed SHetA2 with respect to efficacy 
and IC50. The results for compounds 6-8 are in concurrence with modeling studies, which 
predicted that greater hydrophobicity in ring A would be beneficial. Binding energies were 
determined for compounds docked in silico to mortalin. The urea bridge showed activity 
comparable to or, in some cases, greater than compounds with a thiourea bridge. Several 





Preliminary data revealed that substituting a urea linker for a thiourea linker 
demonstrated that the former exhibited an intramolecular stabilizing H-bonding effect while the 
thiourea did not [174]. Consequently, it is not unreasonable to expect stronger H-bonding 
capabilities by the urea linker compared to the thiourea linker when docked in mortalin. 
Moreover, the oxygen analogues would likely be more stable to oxidative degradation both in 
vivo and in long-term storage. 
 
Figure 7.1 Target compounds 
7.2. Material and Methods  
7.2.1. Chemistry 
In view of the established interaction of SHetA2 with mortalin [26], the nature of the 
heteroatom in ring A and the substituents in ring B were both deemed important.  Consequently, 
the selection of O in ring A and highly polar substituents in ring B were investigated as related to 
biological activity. The influence of larger alkyl groups on ring A was also examined. In an effort 




syntheses were initiated on three additional sets of targets, 6a-c (2-Et-4-Me Series), 7a-d (2-Me-
4-Et Series), and 8a-d (4-Et-4-Et Series). Detailed discussion on the synthesis of compounds is 
out of the scope of this study. For a detailed information refer to [73]. 
All of the substituents attached to ring B in 6-8 had H-bonding capability with polar 
groups in the binding site of mortalin. Members of 6 retained the geminal dimethyl group at C4, 
but a geminal diethyl group was added at C2. Replacement of geminal dimethyl groups at C4 
with geminal diethyl groups in 7 allowed an assessment of the geometric effects of the larger 
ethyl groups on the activity. System 8, with geminal diethyl groups at both C2 and C4, should 
increase the overall capacity to interact with hydrophobic centers in mortalin. Increasing the 
hydrophobic properties of the systems was envisioned with the 2,2,4,4-tetraethyl analogues (2-Et-
4-Et, Series 8). 
 
7.2.2. Modeling Studies 
Autodock 4.2 [15] was used to dock the compounds to the substrate binding domain of 
mortalin (Protein Data Bank ID: 3N8E). For the individual compounds ChemSketch™ 
(Advanced Chemistry Development, Inc. ADC/Labs, Toronto, Ontario, Canada) was employed to 
generate the SMILES notations which were subsequently converted to PDB files with initial 
three-dimensional coordinates using Open Babel GUI [162]. AutoDockTool [175] was then used 
to prepare the protein with partial charges and ligand with rotatable bonds. Only polar hydrogens 
were retained in the molecules. Gasteiger united atom partial charges and solvation parameters 
were assigned. The search space of 44 Å*47 Å*41 Å was slightly larger than the protein 
molecule, and the grid spacing was 0.375 Å. Autogrid was run first to prepare the coordinate 
system and the Lamarckian genetic algorithm was applied with a population size of 150 and 5 




and receptor was recorded. All dockings were performed on an iMac computer with a 2.4 GHz 
intel Core i3 processor and with 4 GB RAM. 
 
7.3. Results and Discussion 
To verify whether compounds shown in Figure 7.1. have the biological effects expected 
from the chemical structural changes to SHetA2, all compounds were screened against A2780 
human ovarian cancer cells by Tim Pouland and Doris Benbrook in the Department of Obstetrics 
and Gynecology, Stephenson Cancer Center, University of Oklahoma  Health Sciences Center. 
The potency (half-maximal inhibitory concentration, IC50) and efficacy (the maximal inhibition of 
cancer cell growth), have been listed in Table 7.1.  
The cell count and ligand concentrations obtained from MTT assay, has been plotted by 
fitting a sigmoidal function. Figure 7.2A shows this sigmoidal fit for SHetA2 and Figure 7.2B is 
the plot for compound 7c. IC50 values are found from this plot and depicted in Figure 7.4. the 
horizontal axis shows the concentration of the ligand and the vertical axis is the cell counts. 
 
Figure 7.2 Sigmoidal plot for (A) SHetA2 and (B) analog 7c 
The MTT Cell Proliferation Assay measures the cell proliferation or the reduction in cell 
viability in the case of apoptosis or necrosis. Cells are stained by a dye which has different color 
in viable(living) versus dead cells. Then the absorbance is measured by a spectrophotometer in 




an indicative of a reduction in the rate of cell proliferation. The effectiveness of the compound in 
causing death of cells can be measured by a dose-response curve. 
The interactions of the compounds with the mortalin substrate-binding domain were 
studied by virtual docking, with the resulting binding free energy values (-ΔG) also listed in 
Table 7.1. Potential correlations between binding energy and potency, between binding energy 
and efficacy, and between potency and efficacy are displayed in Figures 7.3A, B, and C, 
respectively. All compounds showed various degrees of growth inhibition. In Figure 7.3A, a 
significant positive correlation (Pearson correlation coefficient r = 0.52 with p = 0.007) between 
the energy and potency values was observed, which was consistent with compounds having 
stronger binding affinities for mortalin (higher -ΔG values) and greater potency (lower IC50 
values). In Figure 7.3B, a significant negative association (r = –0.60, p = 0.001) between the 
energy and efficacy values was observed, which was consistent with compounds having stronger 
binding affinities for mortalin (higher -ΔG values) and having higher efficacy (higher % 
inhibition).  In Figure 7.3C, the potency and efficacy values for these compounds showed a 
significant negative correlation (r = –0.51, p = 0.008), which was consistent with the expectation 
that a compound with a smaller IC50 has higher efficacy in competing for the receptor mortalin 
versus its partner proteins. In this plot, a sigmoid curve was sketched to capture the main trend in 
the data. Most compounds with IC50 below 5 μM demonstrated efficacy comparable to or better 
than that of SHetA2. Since a small IC50 value necessarily means a stronger affinity for receptor 
binding, the data seemed to indicate that these compounds needed to have a binding affinity 
above a certain threshold to effectively inhibit the cancer cells. This threshold is likely 
determined by interactions between the receptor and its client protein(s), which are competitively 





Table 7.1 IC50, Efficacy, Standard Errors of Mean (SEM), and binding free energy (ΔG) of 












SHetA2 3.17 0.05 84.3 0.7 8.5 
2a 6.97 0.08 87 6 8.1 
2b 4.3 3.0 26 10 8.0 
2c 4.7 0.2 22 4 7.8 
2e 6.9 0.9 32 2 8.3 
3a 4.1 0.1 79 4 8.5 
3c 3.6 0.1 88.4 1.4 7.9 
3d 4.7 0.3 93 3 8.6 
3f 4.56 0.05 91.5 0.8 7.7 
4a 6.4 0.6 19 5 7.8 
4b 5.5 1.5 28 0.6 7 
4c 4.3 0.4 16 6 7.3 
5a 6.7 0.2 74 11 8.3 
5b 5 0.3 47 2 7.8 
5c 3.5 0.4 36 3 8.1 
6a 2.9 0.1 93.9 0.5 8.5 
6b 2.17 0.04 93.2 0.1 8.3 
6c 2.45 0.04 92.4 0.1 8.1 
7a 3.69 0.04 95.7 0.4 8.4 
7b 4.7 0.5 11.8 0.9 8.2 
7c 2.05 0.02 93.66 0.05 8.4 
7d 2.43 0.05 93.3 0.1 8.6 
8a 4.6 0.2 94.00 1.00 8.7 
8b 2.09 0.02 91.4 0.3 8.7 
8c 2.0 0.1 86.2 0.6 8.8 










Figure 7.3 Assessment of (A) binding energy-IC50, (B) binding energy-efficacy, and (C) IC50-
efficacy correlation for all compounds investigated in this study. 
Data for the lead compound SHetA2 was represented by “X”, the 2-Me-4-Me series by red 
triangles, the 2-H-4-Me series by green squares, the 2-Et-4-Me and 2-Me-4-Et series by blue 
circles, and the 2-Et-4-Et series by black diamonds. Moreover, filled symbols were used for 
compounds with oxygen atoms in both the linker and ring A positions, while empty symbols are 
used for compounds with oxygen in ring A and sulfur in the linker.  Data in (C) was fitted by a 
sigmoid curve with half-activity concentration of 4.9 μM. 
The most desirable properties of the target molecules were observed as a combination of 
the smallest IC50 and the highest efficacy. The group of compounds 6b, 7c, and 8b (X=NO2 , 
Y=O) are clearly shown as the best in Figure 7.3C, demonstrating excellent efficacy values of 91-
94% and IC50 values of 2.0-2.4 μM, both of which are a significant improvement over SHetA2 
(84% and 3.2 μM). These three most active compounds had three common chemical features. 
First, all possessed increased hydrophobicity due to the presence of geminal diethyl groups 
instead of the geminal dimethyl groups in ring A. Second, they all had a urea linker (Y = O). 
Third, they had a nitro group (X = NO2) attached to ring B. Docking studies showed that the NO2 
group is capable of forming two hydrogen bonds with the amino acids on mortalin, enhancing the 
ligand-receptor binding affinity. The second best group of 6c, 7d, and 8c (X=CF3 and Y=O) had 
IC50 and efficacy values only slightly lower than the first group. They differed from the first 
group only in the third chemical feature mentioned above, the identity of the polar group attached 
to ring B, indicating that CF3 was slightly less effective than NO2. The third group of 6a, 7a, and 
8a (X = NO2 and Y = S) varied from the first group (6b, 7c, and 8b) only in the second chemical 
feature, having a thiourea instead of a urea linker. Their efficacy values were comparable to or 
even slightly better than the first groups, which might be attributed to a more flexible thiourea 
linker compared to the stiff peptide bonds involved in the urea linker.  However, the third group 
had much lower potencies (higher IC50 values) than the first group.  The importance of the first 
chemical feature, increased hydrophobicity due to the larger ethyl groups in compounds 6-8 can 




and 5(2-H-4-Me), both of which had reduced hydrophobicity due to the absence of the C2 
geminal dimethyl. 
Nevertheless, compounds 8 (2-Et-4-Et) underperformed relative to compounds 6 (2-Et-4-
Me) and 7 (2-Me-4-Et), which might indicate that the chroman unit in 8 became too large with 
geminal diethyl groups at both C2 and C4.  Compounds 6 appeared to have slightly more 
consistent performance than 7, noting that 7a had relatively large IC50. It seemed more beneficial 
to place the geminal diethyl groups at C2 (as in compounds 6) than at C4 (as in 7), a point to be 
justified by molecular docking studies (vide infra).  Therefore, the appropriate amount of 
hydrophobicity, the size of the chroman unit, and the position of the geminal diethyl groups in 
ring A might all have influence on the receptor binding and cancer inhibition. The remaining 
compounds in the 6-8 groups [7b (X=CF3 with Y=S) and 8d (X=OCF3 with Y=O)] exhibited less 
valuable performance. 
 The major difference between the two 2-Me-4-Me series 2 and 3 was that the former had 
a thiourea linker and the latter a urea linker.  Both retained geminal dimethyl groups as in 
SHetA2, but the sulfur heteroatom in ring A was replaced by oxygen.  Compounds in series 2 
displayed a weak performance with respect to both efficacy and IC50 values.  Compounds in 
series 3 demonstrated efficacy comparable to or slightly better than SHetA2, but all had higher 
IC50 values.  Quality performance occurred when both the linker and the chroman heteroatom 
were oxygen or sulfur (as in SHetA2), but the properties deteriorated when the hereroatoms in 
these two fragments were different. This peculiar requirement might be connected with the 
flexibility of the linker, with the thiourea linker being more flexible than urea linker, and the 
ability to form hydrogen bonding with the receptor (vide infra).  Structures 2a and 5a are also 
somewhat unusual in the sense that they possess respectable efficacy values, but have modest IC50 
values. Of course, the possibility exists that a different receptor might conceivably be involved. 
 Figures 7.3A and 7.3C showed the structure model of 7c, one of the best compounds, 




oxygen h-bonded with S473 and the nitro group h-bonded with Q517.  Therefore, the preference 
for having a urea linker and a nitro group can be understood as they are strong hydrogen bond 
acceptors, while sulfur has been shown to be a rather poor H-bond acceptor [176].  Nevertheless, 
this docking conformation was not static as several other docking conformations with similar 
binding energies found different amino acid h-bonding partners.  This conformational diversity 
contributed entropically to the stabilization of the protein-ligand complex [177, 178].  However, 
such a conformational entropic contribution is a challenge to quantify, and it was not considered 
in the binding energies reported in Table 7.1. The chroman ring A with methyl and ethyl 
attachments was accommodated in the hydrophobic pocket formed by residues V482, L450, I447, 
and the methyl of T449 (Figures 7.4B and 7.4C). This is consistent with a report that mutation of 
V482 to phenylalanine abrogated the interaction with tumor suppressor protein p53 [27], likely 
because the bulky side chain of phenylalanine at that position tends to significantly reduce the 







Figure 7.4 Molecular docking of compounds 7c and several other compounds with the substrate-
binding domain of mortalin (PDB ID: 3N8E).  
(A) The complex with compound 7c. (B)-(C) Two views of the same complex highlighting the 
amino acids in contact with 7c. The two hydrogen bonds were indicated by green dotted lines. 
(D)-(G) Comparison of hydrophobic ring A conformations between 7c and SHetA2, 5a, 6b, and 
8b, respectively, where 7c was shown in thicker lines. These four figures were viewed from the 
other end of the tunnel opposite to Figure 7.3A. 
 
In Figures 7.4D-G, the conformations of the hydrophobic ring A of SHetA2, 5a, 6b, and 
8b were compared with that of 7c. All compounds docked in the same hydrophobic pocket of the 
substrate-binding channel, yet with subtle but important differences. In comparison to SHetA2, 
ring A of 7c (X=NO2 , Y=O, 2-Met-4-Et) was pushed further toward the opening of the tunnel 
(closer to the viewer) by the bulky diethyl groups (Figure 7.4D).  Therefore 7c was expected to 




5a with only one dimethyl pair, retreated from the opening since the smaller ring posed less steric 
hindrance to being drawn by polar groups (including the nitro group) into the binding cavity 
through interaction with the protein (Figure 7.4E). Therefore, 5a (X=NO2, Y=O, 2-H-4-Met) was 
expected to be less effective in displacing the client protein. Relative to 7c, in compound 6b 
(X=NO2, Y=O, 2-Et-4-Met) the diethyl pair switched position with the dimethyl pair.  In order to 
pack the more hydrophobic diethyl groups, ring A roughly flipped by 180º, taking the heteroatom 
oxygen from the channel opening to the interior of the hydrophobic pocket (Figure 7.4F). Such a 
flip also caused the nitro group to switch its hydrogen bond partner to R513. Consequently, ring 
A of 6b was slightly more distant from the channel opening than 7c. The docking conformation 
of 8b (X=NO2, Y=O, 2-Et-4-Et) nearly overlapped that of 7c, since in 8b diethyl groups simply 
replaced the dimethyl groups next to the heteroatom. As discussed earlier, 6b and 8b had nearly 
the same biological activities as 7c. 
 
7.4. Conclusions 
Guided by the results from our docking studies of SHetA2 analogs that indicate 
hydrophobicity is an important factor in the binding of the ligand and increasing the 
hydrophobicity leads to higher affinity to the SBD mortalin, several analogs were synthesized and 
biological studies were conducted to mainly study the effect of hydrophobicity of the ligand on 
the potency and efficacy of the binding. The effect of various substituents on ring A and urea and 
thiourea linker was tested as well.  
 It was shown that electron-withdrawing groups (NO2, CF3) on the B ring elicited IC50 
values and efficacy responses as good as or better than that of SHetA2. Moreover, the best 
examples also had geminal diethyl groups replacing geminal dimethyl groups at C2, including 
either O or S in ring A. When geminal diethyl groups were placed at both C2 and C4 of ring A, 




two geminal diethyl groups appeared to make ring A too bulky to be accommodated in the 
binding site of mortalin. Compared to SHetA2, the most exceptional agents were 6b, 7c, and 8b, 
exhibiting efficacy values of 91-94% with IC50 values of 2.0-2.4 mM (SHetA2 had 84% and 3.2 
mM, respectively). In general, the presence of a urea linker between rings A and B gave 
improved activity compared with a thiourea linker. Binding of 7c in the substrate binding site of 
mortalin resulted in H-bonding of the urea oxygen with amino acid S473 and H-bonding of the 
nitro group with Q517. All compounds docked in the hydrophobic pocket with binding ΔG values 
ranging from 7.0 to 8.8 kcal/mol. These binding energies were consistent with a common binding 
site for all compounds. Some fine tuning of related structures is expected to enhance the 










The currant chapter is an overview of our paper on studying the Tetrahydroquinoline 
units in heteroarotinoids and their anti-cancer activities. 
  Nitrogen occurs in a very high percentage of FDA approved pharmaceuticals [179]. The 
N atom renders weakly basic compounds with good H-bonding properties, allowing them to bind 
to a wide range of proteins. Thus, nitrogen analogs of SHetA2 (Figure 8.1) are reasonable 
candidates for evaluation in ovarian cancer screens. the current work utilized a 
tetrahydroquinoline ring A series to assess the activity of analogs with a carbonyl group and a 
hydroxyl group in ring A, with both thiourea versus urea linkers and various substituents in ring 
B.  
A series of compounds having a tetrahydroquinoline (ring A) connected by a urea or 
thiourea linker to a 4-substituted benzene (ring B) has been prepared and evaluated relative to 
SHetA2 in terms of inhibition of A2780 ovarian cancer cells. Six of the derivatives had equal or 
higher efficacy than SHetA2. Series 1, lacking the methyl on the ring A nitrogen and the gem-
dimethyls on the adjacent carbon (R, R' = H, G = CH2), showed only weak activity. Salt 2, the 




In the cell line studied. Series 3 compounds, which had these two modifications in ring A (G = 
CO and N-CH3 replacing the heteroatom S in SHetA2), were most successful.  Compound 3a (R, 
R' = CH3, G = C=O, Y = O, Z = NO2) had much better efficacy (defined as the maximal 
inhibition of cancer cell growth, 94.8%) than SHetA2 (84.3%), but slightly worse potency 
(measured by half-maximal inhibitory concentration IC50 3.8 μM) than SHetA2 (3.2 μM). In 
addition, in series 3, Z = CF3 (3c and 3d, Y = O and S, respectively) and Z = OCF3 (3e and 3f) 
were also evaluated since these are also electron-withdrawing groups with H-bonding capability. 
Both displayed excellent potency and efficacy. Compounds 3e and 3c showed improvement in 
both efficacy and potency. In general, when the linker group between rings A and B was urea, 
efficacy values modestly exceeded those with a thiourea linker in the carbonyl-containing 
tetrahydroquinoline systems (series 3). In contrast, when ring A possessed the 1,2,2,4,4-
pentamethyltetrahydroquinoline unit with a C3 hydroxyl group (G = CH(OH) series 4), very poor 
efficacy and potency were observed. Model compound 5 (G = CH2, R’ = R = CH3, Y = S, 
Z=NO2), which differed from SHetA2 only at the heteroatom (N-CH3 versus S) in ring A, 
demonstrated improved efficacy (91.7%) but less potency (4.5 μM IC50). 
 




8.2. Material and Methods 
 The preparation of members of 1 is out of the scope of this study. The target structures are 
listed in Figure 8.2. 
 
 
Figure 8. 2 Structure of compound series 1, 2, 3, 4, and 5 
All of the compounds were fully characterized by IR, 1H NMR, and 13C NMR analyses.  Final 
products were also confirmed by elemental analyses.   
 
8.2.1. Biological Section 
 The biological tests have been performed by Doris Benbrook and colleagues in the 
Department of Obstetrics and Gynecology, Stephenson Cancer Center, University of Oklahoma  
Health Sciences Center. The compounds were dissolved in DMSO at a concentration of 0.01 M. 
The human ovarian cancer cell line A2780 was treated and dose-response curves were fitted to 
extract the IC50 and efficacy (the maximal % growth inhibition) parameters.  




8.2.2. Theoretical Docking Methods 
  AutoDock 4.2 [15] was used to dock the compounds to the substrate binding domain of 
mortalin (Protein Data Bank ID: 3N8E). For the compounds, ChemSketchTM (Advanced 
Chemistry Development, Inc. ADC/Labs, Toronto, Canada) was used to generate the SMILES 
notations, which were subsequently converted to PDB files with initial three-dimensional 
coordinates using OpenBabelGUI [162]. AutoDockTool (ADT) [175] was then employed to 
prepare the protein and compounds with partial charges and for the latter rotatable bonds too. 
Only polar hydrogens were retained in the molecules. Gasteiger partial charges and solvation 
parameter were assigned. The search space of 44 Å × 47 Å × 41 Å was slightly bigger than the 
protein molecule and the grid spacing was 0.375 Å.  Autogrid was run first to prepare the 
coordinates system and then Lamarckian genetic algorithm was applied with a population size of 
150 and 25 million maximum evaluations. The minimum empirical binding free energy (ΔG) 
between the compound and receptor was reported.  The dissociation constant Kd is calculated 
from binding free energy using the relation ΔG = –RT ln(Kd), where R is the gas constant.  All 
dockings were performed on an iMac computer with a 2.4 GHz Intel Core i3 processor and 4 GB 
RAM. 
 
8.3. Results and Discussion 
The biological activities of all compounds were validated by screening with A2780 
human ovarian cancer cells (Table 8.1). The half-maximal inhibitory concentration (IC50) and 
efficacy for all compounds revealed a range of growth inhibition. The Pearson correlation 
coefficient between the two parameters was –0.82, indicating a highly negative correlation. This 
is consistent in that a compound with a smaller IC50 is usually more effective to compete for the 




 To better assess the dose-response results, data in Table 8.1 were visualized by plotting the 
efficacy against IC50 (Figure 8.3).  In this plot, a sigmoid curve was sketched to capture the main 
trend in the data.  Most compounds with IC50 below 5 μM demonstrated efficacy comparable to 
or better than that of SHetA2.  Moreover, a small IC50 also usually means a stronger affinity for 
the compound to bind with its protein receptor.   
 
Table 8.1 IC50, efficacy, ΔG, and dissociation constant (Kd) values for different compounds 
docked to the mortalin substrate-binding domain.  
 
   Cpd  Y Z IC50 (μM) Efficacy (%)  –ΔG (kcal/mol)   Kd (μM) 
SHetA2 S NO2 3.17 ±0.05  84.3 ±0.7        8.5       0.6 
1a  O NO2 6.9 ±0.2  17.1 ±1.2        8.2       1.1 
1b  S NO2 7.1 ±0.3  17.8 ±1.6        7.9       1.6 
1c  S CF3 6 ±0.2   42 ±3         7.5       3.3 
1d  S OCF3 7.1 ±0.8  24 ±2         7.2       5.4 
2  O NO2 6.6 ±0.3  22 ±4         8.5       0.7 
3a  O NO2 3.8 ±0.1  94.8 ±2.2        8.9       0.3 
3b  S NO2 4.4 ±0.2  91.4 ±1.7        8.2       1.1 
3c  O CF3 2.58 ±0.08  90.1 ±1.4        8.0       1.5 
3d  S CF3 3.9 ±0.1  90.8 ±2                7.9       1.6 
3e  O OCF3 2.4 ±0.2  91.3 ±1.3        7.9       1.8 
3f  S OCF3 5.4 ±0.6  76 ±8         7.7      2.4 
3g  S NH2  7.7 ±1.4  24 ±4         8.2       1.1 
4a  O NO2 8.4 ±1.9  26 ±4         8.0       1.6 
4b  S NO2 10 ±5   25 ±4         7.7       2.3 
4c  O CF3 6.7 ±0.5  25 ±5         8.4       0.7 
4d  S CF3 7.8 ±0.2  23.6 ±3.3        8.2       1.1 
4e  O OCF3 7.6 ±0.7  56.1 ±2.4        7.7       2.3 
4f  S OCF3 13.1 ±6.1  15.3 ±3.3        7.6       2.9 








Figure 8.3 Assessment of the efficacy to IC50 relation for all compounds. 
 The data indicate that a compound must have an affinity above a certain threshold for its 
receptor in order to be effective in initiating the destruction of cancer cells.  This threshold is very 
likely determined by interaction between the receptor and its substrate protein(s), which is 
competitively displaced by the synthetic ligand.  The most desirable properties of a molecule are 
a combination of the smallest IC50 and the highest efficacy. A small IC50 is advantageous when 
translating from single-layered cell cultures to real tissues where a lower concentration of the 
compound may be available. Compounds 3a-e showed higher efficacy than SHetA2, with 3a 
exhibiting the highest efficacy of 95%. The members of 3 had IC50 values of 2.58 μM (3c) and 
2.4 μM (3e), better than that of SHetA2 (3.17 μM). 
The interactions of the compounds with the mortalin SBD were studied by virtual 
docking with Autodock. The binding free energies (ΔG) and dissociation constants (Kd), where a 
smaller Kd value reflects a stronger binding affinity, are reported in Table 8.1.  The Pearson 
correlation coefficient between the Kd and IC50 was 0.32, indicating a weak positive correlation.  
Partially this weakness in correlation may be due to the relatively low accuracy of ΔG and Kd 




IC50, which was obtained from cell-based assays, with the dissociation constant Kd, which was 
calculated from binding free energy.  
IC50 depends on the cellular concentration of the receptor (mortalin in this case) and is 
higher than Kd, obeying IC50 = [R]0/2 + Kd(1+[S]/KM), where [R]0 is the receptor concentration 
and [S] the concentration of the substrate protein (for example p53) being competitively displaced 
by the drug, and KM the concentration of the substrate protein at which the receptor achieves half 
activity [180].  The intercept (2.5 ± 1.7 μM) of the fitting line indicated that the mortalin 
concentration in A2780 cancer cells was roughly 5 μM, and, for this reason, it might be difficult 
to obtain IC50 values much lower than 2.5 μM for these analogs.  
 
 
Figure 8.4 IC50- Kd  graph. 
Assessment of IC50 of the compounds and their calculated biochemical dissociation constant (Kd) 
with the mortalin substrate-binding domain.  





Figure 8.5 Molecular docking of compounds 
(A) 5, (B) 3e, and (C,D) 3a to mortalin SBD (PDB ID 3N8E) at the peptide-binding pocket. 
Amino acids in contact with the compounds were shown in surface drawing method, and the 
compounds in sticks. Carbon atoms of the amino acids were shown in tan and carbon of 
compounds in cyan, nitrogen in blue, oxygen in red, sulfur in yellow, and fluorine in green. 
 
 Protein-ligand interactions were illustrated in Figure 8.5 for several compounds. The docking 
pose of compound 5 (Figure 8.5A) was very similar to that of SHetA2 [73], with the negatively 
charged NO2 group being attracted to the positively charged sidechain of R513, the backbone 
C=O of S473 being hydrogen-bonded to the thiourea linker, and ring A with methyl groups 
residing in the hydrophobic part of the pocket. The docking pose of compound 3e was opposite to 
those of SHetA2 and 5. This might be a consequence of the reduced hydrophobicity in ring A 
with the addition of oxygen and nitrogen atoms. In addition to the hydrogen bonds involving the 
linker, there were two more hydrogen bonds formed between OCF3 oxygen and E483 amide, and 




D) was also opposite to SHetA2.  The linker C=O also formed hydrogen bond with L450 amide. 
The NO2 group formed hydrogen bond with K485 amide group.   
   
8.4. Conclusion 
 Several sets of compounds having a Ring A tetrahydroquinoline linked by means of a urea or 
thiourea to a 4-substituted benzene (Ring B) have been prepared and evaluated relative to SHetA2 
in terms of inhibition of A2780 ovarian cancer cells. Six of the derivatives had equal or greater 
efficacy than SHetA2. For compounds 1a-1d [series 1], the nitrogen analogs of SHetA2 without a 
methyl on the Ring A nitrogen or the gem-dimethyls at C2, showed only weak activity. 
Compound 2, the quaternized N,N-dimethyl iodide salt of 1a, also lacked significant percent 
growth inhibition and efficacy in the cell line studied. Structures incorporating a permethylated 3-
oxo-1,2,3,4-tetrahydroquinolin-6-yl) linked to a 4-nitrobenzene (3a and 3b) were essentially 
equivalent in percent of growth inhibition to SHetA2, but with the former having better binding 
affinity [Kd] values. In addition to NO2 at C4 of Ring B, CF3, (3c and 3d) and OCF3 (3e and 3f) 
were also evaluated and found to exhibit high growth inhibition and efficacy. Surprisingly, for the 
derivative having Z = NH2 (3g), the IC50 and efficacy were weak.  In the carbonyl-containing 
tetrahydroquinoline systems [series 3], efficacy and growth inhibition values were modestly 
higher when the linker group between ring A and B was a urea versus a thiourea.  In contrast, for 
compounds having a 1,2,2,4,4-pentamethyl-3-hydroxytetrahydroquinoline unit [series 4], the 
efficacy and the percent  growth inhibition varied only slightly, both being less effective than 
other analogs. An additional compound 5 was also examined for comparison purposes. In this 








Making use of computational tools alongside experimental techniques is a very useful 
approach in drug design. We studied the structure of mortalin using solution NMR and found 
high similarity to the crystal structure expect the more flexible unstructured C-terminus. We also 
studied the interaction between SHeA2 and substrate binding domain of mortalin via solution 
NMR spectroscopy and molecular mechanic tools, GROMACS and Autodock. The result of these 
studies led us to design improved analogs. Several of these analogs were synthesized and further 
computational studies and biological tests have been performed on them. By studying the effect 
of various structural changes on SHetA2, we showed that some of these compounds outperform 
SHetA2 in terms of efficacy and potency. We performed molecular mechanic studies for several 
mutants of mortalin SBD and NMR spectroscopy studies for several other analogs of SHetA2 
(not included in this paper). All in an attempt to find the most involved residues of the receptor 
protein in interaction with ligand and the most effective atoms of the ligand in order to design 
analogs with high efficacy and potency with enhanced ability to competitively bind to mortalin 
and abrogate mortalin-p53 interactions. Our findings helps designing more promising SHetA2 
analogs. 
Future work includes studying the effects of mutants in the binding, biological tests of the 
suggested mutants, designing and testing other SHetA2 analogs to test the efficacy, potency, 
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